¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/10/7 ¤W¤È 07:59:29
²Ä 4683 ½g¦^À³
|
¼Æ¾Ú2¦n1Ãa>>ì¨Ó³o´N¬O¶^ªºì¦]¡A¦ý¤£¸Ñªº¬O¡A³oºâ¸Ñª¼¥¢±Ñ¶Ü?
¦pªG¯uªº«Ü®t¡A«ç¥i¯à¶Òªº¨ì¸êª÷¡A§ë¸ê¾÷ºc¤£¬O²Â³J§a?
ÁÙ¬O»¡»´¯gªº¼Æ¾Ú¤Ó¤Ö¡A¤§«áªº¼W¶q¸ÕÅ禳¾÷·|§ïµ½? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/10/6 ¤U¤È 10:07:25
²Ä 4682 ½g¦^À³
|
¦Ñ·à¬O«j±j©ê¦í¡A¥i¬O¤ß¤¤¥Rº¡ºÃ´b¤ÎµL©`
´Nºâ½æ¤F¤]¤£È¿ú
¤@®a¤½¥q¦h¦¸¸Ñª¼¡A±q¥¼¦¨¥\ ¬O¤½¥q¤Hû¯à¤O¤£¨¬¡AÁÙ¬O¤H¿Ñ¤£»N
¯u¬Û¤£©ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/10/6 ¤U¤È 08:22:48
²Ä 4681 ½g¦^À³
|
¨ä¹ê§NÀR·Q·Q ·à¤l²{¦b´Nºâ¦AÁV¶^¨ì1¤¸¥H¤U ¦n¹³¤]¨SÁx¹DÀù¸Ñª¼¥¢±Ñ·Ç³Æn¤U¥«®ÉÁV ¨º®É¤]´¿¶^¨ì1¤¸¥H¤U¡A¦Ó¥B¤½¥q¸êª÷ÁÙ§Y±N¥ÎºÉ ²{¦b¤½¥q¤âÀY¤]ÁÙ¦³¨¬°÷ªº¸êª÷Ä~Äò2b ¸ò¨º®É§ÖnÃz±¼¤]¦³©Ò¤£¦P ¨º®É¤£¨ì1¤¸³£©ê±o¦í¡A³o¦¸·íµM¤]¯à ·à¤lnª§®ð¤@ÂIªü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 08:13:08
²Ä 4680 ½g¦^À³
|
¦³Dupilumab ¤T´Á1377¤H(919+460) °O¿ý.
dupilumab »´ °ò½uTRAC< 1115pg/ml,¥§¡EASI25 ,16¶gªvÀø«á¥§¡°EASI77% ¤¤ °ò½uTRAC >1115 <4300pg/ml ,¥§¡EASI31,16¶gªvÀø«á¥§¡°EASI67% « °ò½uTRAC >4300 pg/ml,¥§¡EASI41,16¶gªvÀø«á¥§¡°EASI65%
¦Xp ¥§¡ °ò½uTRAC >6100 pg/ml,16¶gªvÀø«á¥§¡°EASI70%
¤T²Õ16ªvÀø«áEASI ¥§¡°´T70%. ¥NªíADªº±w¯f¾÷¨î¨Ã«D¥u°_¦]IL4/IL13.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/10/6 ¤U¤È 08:05:56
²Ä 4679 ½g¦^À³
|
¤½¥q¬O¸Ó¥X¨Ó»¡©ú¤@¤U¨S¿ù ¦ý¬O¼Æ¾Ú³oºØªF¦è¤@½¨âÀü²´´Nºâ »¡©úªº¦A²M·¡®£©È¥«³õ¥¼¥²¶R³æ
¦p¦P¤Ñ©R¤j»¡¦b¦h¡A¤ß¤¤ªººÃ°Ý ®£©ÈÁÙ¬OºÃ°Ý¡A¦³¼W¥[¤F¦h¤Ö«H¤ß¶Ü¡H ¤£¤@©w¤Ï¦Ó¤Þ°_¤Ï§@¥Î |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 07:49:54
²Ä 4678 ½g¦^À³
|
¼Æ¾Ú2¦n1Ãa.
¦nªº2/3ªº«¯g,¦n¨ì´Î´Î¥s.
Ãaªº1/3,³s»´¯g¤]ªv¤£¦n.
¤½¥q¤v«Å§i¦Pµ¥¯Å³Ì¨Î.
¸ÑŪÀH¤H.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/10/6 ¤U¤È 07:42:25
²Ä 4677 ½g¦^À³
|
¼Æ¾ÚÀu¬°¦óªÑ»ù¤@ª½¶^
¬O¥~°ê¤H½M¤F²´¶Ü
³oùر¤@©w¦³¿ß¿°
ªÑ»ù«ùÄò¶^¡A¦p¦³»~·|
¤½¥q¬°¦ó¤£°µ¼á²M»¡©ú
¬O§@¸é¤ßµê§a
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 07:07:51
²Ä 4676 ½g¦^À³
|
¬õ¹Ð¤j
9/27 1b ¸Ñª¼
ASLAN004 ªvÀø¸û«¯g(°ò½u¥§¡EASI30.5,TRAC>4000 pg/ml),16¦ì«D±`¦³®Ä.¹w¦ô16¶gªvÀø¤ñDupilumabÁÙ¦n¤@¯Å. (¥«³õ³W¼Ò¦ô»´¯g1/3)
--------------------------------------------
RITT ASLAN004 16¤H¡A8¶gªvÀø¡C
°ò½uEASI 30.5 TRAC.>4000 pg/ml
§t3¦ì¤¤Â_¡A¤¤Â_²v3/16=19%
RITT ¥§¡°´T65% ¥Ñ©ódupilumab ¤T´Á¤¤断²v¶È7%.
RITT 16¡K¡K¤¤断°²³]¤U׬°1¤H¡A
16¡Ñ65%/14=74%
¥t¥~9-16¶gªvÀø¡A¦ô¥t¥~¼W¥[8%,74%+8%=82%ªº´Á±æÈ 16¶gªºRITT/REEPP¡C
Dupilumab 3´ÁÁ{§É¡A°ò½uCCL13/TRAC >1155pg/mlªº16¶gªvÀø«áEASI¥§¡°´T63%-67%.
¡«áEASI ¥§¡°´T ASLAN004 VS Dupilumab
82% vs 63%-67%
ASLAN004 22%-30% ¡AÀu©óDupilumab¡K¡K°ª¥Íª««ü¼Ð(«¯g/°ò½u>EASI31) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 06:53:15
²Ä 4675 ½g¦^À³
|
¬õ¹Ð¤j,
9/27 ¸Ñª¼,³Qç°£¬Y¤@¤¤¤H¤ß9(6+3) ¦ì ¬Ò»´¯g.(°ò½uEASI 18~19),TRAC<1200 pg/ml,
ASLAN004 ²Õ6¦ì,ªvÀø8¶g¥§¡°§CEASI 50% ----²z½×¤W¦b¶gn°¨ì65%~70%----
¹ï·Ó²Õ3¦ì ªvÀø8¶g¥§¡°§CEASI 50%
¨â²ÕµL®t²§. (p>0.05,没¹LÃö)
------------------------------- ¦ýDubilumab ¤T´Á, »´¯gTRAC <1115pg/ml,¥§¡°ò½uEASI24~25ªvÀø«á¤]¦P¼Ë¦³®Ä. ¦³«Ý2b Á{§É,ÂX¤j¤H¼Æ»´¯g20:20 ¤H,16 ¶gªvÀø«á ¤§¦AÅçÃÒ. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/10/6 ¤U¤È 06:35:17
²Ä 4674 ½g¦^À³
|
¤Ñ©R¤j 004¬O»´¯gªº³¡¤À¤£²z·Q¶Ü¡H À³¸Ó²z½×¤W¹ï«¯g¦³®Ä¡A¹ï»´¯g¤@©w¤]¬O¦³®Äªº
¦ý¹ï»´¯g¦³®Ä¡A´N¤£¤@©w¹ï«¯g¦³®Ä¤F ³o¬O¨Åé¦ÛµM¤ÏÀ³§a
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 05:59:09
²Ä 4673 ½g¦^À³
|
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis 2014 www.nejm.org/doi/10.1056/NEJMoa1314768
CORRELATIONS BETWEEN CLINICAL RESPONSE AND BIOMARKERS The Th2 biomarker levels measured at study entry (eosinophil counts, TARC, and IgE) showed weak or no correlation with improvements in the EASI or pruritus scores (as assessed by means of the 5-D and numerical-rating scales) after dupilumab treatment (Table S5 in the Supplementary Appendix). However, significant correlations were observed between reductions in the TARC level and changes in pruritus scores (Table S6 in the Supplementary Appendix). At the end of the 12-week monotherapy study, there was a significant correlation between the percentage change in the TARC level and the percentage change in the scores on the pruritus numerical-rating scale (r=0.53; P<0.001) and the 5-D pruritus scale (r=0.40; P=0.004) (Table S6 in the Supplementary Appendix).
Á{§É¤ÏÀ³©M¥Íª«¼Ð»xª«¤§¶¡ªº¬ÛÃö©Ê ¦b¬ã¨s¶}©l®É´ú¶qªº Th2 ¥Íª«¼Ð»xª«¤ô¥¡]¶Ý»Ä©Ê²É²ÓMp¼Æ¡BTARC ©M IgE¡^Åã¥Ü»P dupilumab ªvÀø«á EASI ©Îæ±Äoµû¤À¡]³q¹L 5-D ©M¼Æ¦rµû¤À¶qªíµû¦ô¡^ªº§ïµ½®z¬ÛÃö©Î¨S¦³¬ÛÃö©Ê¡C ¸É¥Rªþ¿ýªíS5¡^¡C
µM¦Ó¡AÆ[¹î¨ì TARC ¤ô¥ªº°§C»Pæ±Äoµû¤ÀªºÅܤƤ§¶¡¦s¦bÅãµÛ¬ÛÃö©Ê¡]¸É¥Rªþ¿ýªí S6¡^¡C
¦b¬°´Á 12 ¶gªº³æÃĪvÀø¬ã¨sµ²§ô®É¡ATARC ¤ô¥ªº¦Ê¤À¤ñÅܤƻPæ±Äo¼Æȵû©w¶qªíµû¤Àªº¦Ê¤À¤ñÅܤƤ§¶¡¦s¦bÅãµÛ¬ÛÃö©Ê¡]r=0.53¡FP<0.001¡^©M 5 -D æ±Äo¶qªí¡]r=0.40¡FP=0.004¡^¡]¸É¥Rªþ¿ýªí S6¡^¡C
¸É¥Rªþ¿ýÀÉ
P.26 Table S6. Correlations of TARC with Clinical Response Measures (EASI, NRS and 5D) in Study M12 Biomarker/Clinical Response Evaluated* Day 29 Day 85
ªvÀø«áTRAC§ïÅÜVS EASI/Pruritus ªº§ïÅܦ¨¥¿¬ÛÃö,p<0.001
Correlation P-value Correlation P-value Percent change TARC/percent change EASI 0.55 < 0.001 0.37 < 0.01 Percent change TARC/percent change pruritus 5D 0.51 < 0.001 0.40 < 0.01 Percent change TARC/ percent change pruritus NRS 0.47 < 0.001 0.53 < 0.001
TARC level/EASI score 0.66 < 0.001 0.50 < 0.001
TARC level/pruritus 5D score 0.57 < 0.001 0.35 0.005 TARC level/pruritus NRS score 0.45 < 0.001 0.40 < 0.01 *All patients; 12-week monotherapy. EASI denotes Eczema Area and Severity Index; NRS, numerical rating scale, TARC, thymus and activation-regulated chemokine
www.nejm.org/doi/suppl/10.1056/NEJMoa1314768/suppl_file/nejmoa1314768_appendix.pdf |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 04:36:29
²Ä 4672 ½g¦^À³
|
IMMU 2016¦~2¤ë¨ú±oBTD(¬ð¯}©ÊÀøªk) ¤@¦~内¡A¦U¤ëªÑ»ù¡A¦p¤U:
2020¦~ 9¤ë³Q87¬ü¤¸¨ÖÁÊ¡C
Feb 16 2.26 Mar 16 2.50 Apr 16 3.55 May 16 4.84 Jun 16 2.32 Jul 16 2.65 Aug 16 2.77 Sep 16 3.25 Oct 16 2.30 Nov 16 3.22 Dec 16 3.67 Jan 17 4.50 ¡K¡K
ASLAN004 ²³ø¡ABEST-IN-CLASS
Àu©óDupilumab ¤w¨ú±o¨â±iBTD¡C
MOA¤w¸g1b证©ú¦¨¥\¡C¥i¦P®ÉªýÂ_IL4/IL13°T¸¹¶Ç»¼¡C
RITT¥Ø«e2/3¥Ø¼Ð¥«³õ(TRAC>1115)¥i³QASLAN004¥D®_¡C
¨ä¥L´N¬Oµ¥«Ý¡Iµ¥«Ý¡I³Q¨ÖÁÊ¡I¡C
¥i¯ànµ¥2b ¸Ñª¼«e¡B«á¡C
¦]¬°ÁÙn§ä¦^TRAC <1115¡A»´¯g¥«³õ¡C
Ó¤H²`«HDupilumab ¹ï»´¯g¦³Àø®Ä¡AASLAN004¥²¥i¦p¦¹¡C
¦]¬°M0A¬Û¦P¥i¦P®Éªý断IL4/IL13¡A¥@¤W°ß¤G¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 04:06:50
²Ä 4671 ½g¦^À³
|
9.Change from baseline in PD markers of allergic inflammation (TARC and total IgE) weekly up to Week 8. [ Time Frame: Baseline up to Week 8 ] Measurement of absolute values of TARC and total IgE in serum concentration and percentage of change
9.¹L±Ó©Êª¢¯gªº PD ¼Ð»xª«¡]TARC ©MÁ` IgE¡^¨C¶g±q°ò½uÅܤƨì²Ä 8 ¶g¡C [®É¶¡®Ø¬[¡G°ò½u¨ì²Ä 8 ¶g] ´ú¶q¦å²M¤¤ TARC ©MÁ` IgE ªºµ´¹ïÈ©MÅܤƦʤÀ¤ñ
clinicaltrials.gov/ct2/show/NCT04090229
ASLAN004 1b ¨ä¥L¦¸n«ü¼Ð¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 03:50:28
²Ä 4670 ½g¦^À³
|
¤w¥Ó½ÐÃÄ证¡A¦ý¨ä¥L¤å¥ó©µ»~¡A¨ÖÁÊ«eªºªÑ»ù¤£¨ì15¬ü¤¸¡A 1¦~«á¡A87¬ü¤¸³Q¨ÖÁÊ¡C
IMMU¹ê»Ú®×¨Ò¡C
¬ÝªÑ»ù®¶Àú¥h§ë¸êÀò§Q¡A¦b¤p·sÃĤ½¥q¤£®e©ö¡C »·»·§C©ó«ùªÑµ¥¨ÖÁÊ¡C
´x´¤¦íÁ{§É¼Æ¾Ú+¥D®_¥«³õ¼ç¤O¡C
+µ¥«Ý¡C ¡K¡K¤]¤£®e©ö¡C
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ¨ÖÁÊ»ù87¬ü¤¸/ªÑªºIMMU¡A¨ú±oBTD«á¡A ¡A¦]µu´ÁªÑ»ù¤j变°Ê¡A¥¼¨£¨äªø§ë»ùȦÓÂ÷³õªÌ¡A³Ì°ª¤ÖÁÈ37¿¡C
¤@¥Í¤§¾÷·|¤£¦h¡I
¡K¡K¡K¡K¡K¡K
m.investing.com/equities/immunomedics-historical-data
Immu ¤½¥q¡AIMMU132/ADC¡A³Q200»õ¬ü¤¸¨ÖÁÊ¡A¬ù87¬ü¤¸/ªÑ¡C
¤@ADCªv¥|´Á3½u«áBNTC¡A·sÃĤ½¥q¡A¥H2´ÁÁ{§É¥Ó½ÐÃĵý¡AÀòFDAªºBTD(¬ð¯}©ÊÀøªk)¡A
·í2016/¦~02¤ë ÀòBTD®ÉªÑ»ù¶È2.32¬ü¤¸/ªÑ¡A ´¿¸g±NIMMU132¥þ²y¾P°âÅv20¦h»õ¬ü¤¸±ÂÅv¥X¥h¡AªÑ»ùº¦¨ì25¬ü¤¸¡A«á¨Ó¤jªÑªF¶}°£CEO¡A¤£¦P·N±ÂÅv¦X约¡A¤½¥q³Ì«á2050¦~ÀòÃĵý¡AªÑ»ùº¦¨ì40¬ü¤¸¡A³Ì«á³Q¨ÖÁÊ»ù87¬ü¤¸¥ª¥k¡C
·sÃĤp¤½¥q´N¬O³Q¨ÖÁʪѻù³Ì°ª
¦b¬ü°ê¥Í§ÞªÑ«Ü¥¿±`. IMMU-132 °µ§¹ 2´Á,2016/02/06®³¨ìBTD,ªÑ»ù2.32¬ü¤¸/ªÑ
www.adcreview.com/news/breakthrough-therapy-designation-for-sacituzumab-govitecan-in-triple-negative-breast-cancer/
Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer 2016/02/06
Mar 15 3.83 4.11 4.36 3.64 18.00M -6.13% Apr 15 3.60 3.80 4.39 3.56 17.73M -6.01% May 15 3.86 3.62 4.39 3.62 15.98M 7.22% Jun 15 4.06 4.08 5.05 3.85 30.66M 5.18% Jul 15 2.05 4.07 4.32 1.83 51.47M -49.51% Aug 15 2.16 2.05 2.24 1.69 23.05M 5.37% Sep 15 1.72 2.21 2.62 1.50 19.19M -20.37% Oct 15 2.99 1.70 3.09 1.59 21.52M 73.84% Nov 15 3.29 3.01 3.40 2.73 16.66M 10.03% Dec 15 3.07 3.30 3.33 2.66 15.69M -6.69% Jan 16 1.88 2.96 3.02 1.68 15.78M -38.76% Feb 16 2.26 1.87 2.49 1.61 24.49M 20.21% Mar 16 2.50 2.27 2.80 2.21 18.32M 10.62% Apr 16 3.55 2.47 3.86 2.43 21.14M 42.00% May 16 4.84 3.63 4.88 3.41 33.26M 36.34% Jun 16 2.32 4.87 5.44 1.95 95.69M -52.07% Jul 16 2.65 2.33 2.75 2.09 24.27M 14.22% Aug 16 2.77 2.66 3.15 2.60 19.89M 4.53% Sep 16 3.25 2.78 3.43 2.60 18.13M 17.33% Oct 16 2.30 3.21 3.39 2.06 61.00M -29.23% Nov 16 3.22 2.34 3.59 2.02 38.49M 40.00% Dec 16 3.67 3.22 4.10 3.01 32.31M 13.98% Jan 17 4.50 3.65 4.82 3.30 45.15M 22.62% Feb 17 5.00 4.50 5.89 4.08 107.54M 11.11% Mar 17 6.47 5.07 7.15 4.73 90.95M 29.40% Apr 17 5.73 6.53 6.53 5.00 39.59M -11.44% May 17 7.55 5.73 7.97 5.22 87.11M 31.76% Jun 17 8.83 7.53 9.04 7.26 54.69M 16.95% Jul 17 8.56 8.84 9.51 8.10 35.31M -3.06% Aug 17 12.64 8.56 12.66 7.17 72.27M 47.66% Sep 17 13.98 12.90 14.19 10.85 55.97M 10.60% Oct 17 10.72 14.05 14.48 10.22 51.27M -23.32% Nov 17 10.86 10.76 12.83 9.72 66.46M 1.31% Dec 17 16.16 10.69 17.05 8.68 87.42M 48.80% Jan 18 16.67 16.29 18.93 15.20 56.04M 3.16% Feb 18 16.91 16.61 17.42 14.06 40.79M 1.44% Mar 18 14.61 16.92 18.08 14.27 43.78M -13.60% Apr 18 18.21 14.51 18.80 13.82 37.37M 24.64% May 18 22.06 18.11 23.18 17.58 50.37M 21.14% Jun 18 23.67 22.27 26.48 22.10 81.53M 7.30% Jul 18 23.93 23.37 27.33 22.30 37.85M 1.10% Aug 18 26.76 23.77 26.76 20.73 32.45M 11.83% Sep 18 20.83 26.85 26.99 20.06 28.86M -22.16% Oct 18 22.53 20.99 24.15 19.24 43.12M 8.16% Nov 18 20.09 22.71 24.99 16.80 47.75M -10.83% Dec 18 14.27 20.60 21.23 12.86 54.81M -28.97% Jan 19 14.79 14.10 18.61 11.55 104.35M 3.64% Feb 19 15.76 14.71 16.61 13.55 48.56M 6.56% Mar 19 19.21 15.90 19.27 15.90 49.22M 21.89% Apr 19 16.02 19.31 19.51 15.15 49.24M -16.61% May 19 13.07 16.05 16.26 13.01 67.04M -18.41% Jun 19 13.87 12.85 14.05 11.59 64.24M 6.12% Jul 19 14.75 14.27 15.63 13.73 35.38M 6.34% Aug 19 12.80 14.73 16.05 12.47 39.92M -13.22% Sep 19 13.26 12.66 17.55 12.05 59.23M 3.59% Oct 19 16.00 13.21 16.64 12.43 46.10M 20.66% Nov 19 18.78 15.99 19.52 15.90 32.81M 17.38% Dec 19 21.16 18.88 22.22 17.22 67.45M 12.67% Jan 20 18.57 21.26 21.32 17.18 37.22M -12.24% Feb 20 16.00 18.75 20.46 14.58 28.52M -13.84% Mar 20 13.48 16.18 17.27 9.18 65.99M -15.75% Apr 20 30.38 10.86 31.56 8.80 191.25M 125.37% May 20 33.59 29.88 35.47 29.69 65.47M 10.57% Jun 20 35.44 33.20 37.25 29.55 95.03M 5.51% Jul 20 42.23 35.79 44.48 35.62 51.78M 19.16% Aug 20 44.56 42.86 44.91 39.40 29.84M 5.52% Sep 20 85.03 44.54 86.91 37.85 180.01M 90.82% Oct 20 87.86 85.03 87.93 84.91 15.32M 3.33% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 03:19:41
²Ä 4669 ½g¦^À³
|
ªø§ëÀH缘¡I ÀH缘ªø§ë¡I
¦A¨Óµ¥300¤H2b ADÁ{§É¶}©l¡A²Ä1Ó©Û¶Ò¤½§i¡I
¥¿±`»Ý¶}¥ß60Ó¥þ²y©Û¶Ò¤¤¤ß¡C7-8Ó¤ë©Û¶Ò§¹¦¨¡A13Ó¤ë¸Ñª¼¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/10/6 ¤U¤È 02:49:51
²Ä 4668 ½g¦^À³
|
¥«³õ¤W°µÃþ¦üªºÃįuªº¤Ó¦h¤F~³Ìªñ1¦~¨Ó¦³´X®a¬Û¦PÃĪ«1´Á¸Ñª¼«á³£¤jº¦5¦¨~1¿¥H¤W,¦ý¥u¦³¨È·à±d¦V¤U¶^±¼¤@¥bªÑ»ù¥H¤W, ¦pªG¯uªº¦p³oÓªO¤W¤ÀªRªº¼Æ¾Ú¨º»ò¦n,ªÑ»ù¬°¦óÁÙ¬O«®À??Ãø¹D¬O¨º¨Ç§ë¸ê¾÷ºc¥þ³¡¬Ý¨«²´½M¤F¤£±¤¦¨¥»¤@¸ô¨g½æ? ¨Æ¹ê¬O¨È·à±dªº¼Æ¾Ú´N¬O®t©ó¹w´Á,¤§«á¤]¤£·|¦³±Ë»ò¤H·|¨Ó½Í±ÂÅv©Î¬O¨ÖÁÊ,ªÑ»ù±N·|½L¶^¨ì1¶ô¿ú¥H¤U....
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤U¤È 12:57:28
²Ä 4667 ½g¦^À³
|
Dupilumab 3´ÁÁ{§É¡A°ò½uCCL13/TRAC >1155pg/mlªº16¶gªvÀø«áEASI¥§¡°´T63%-67%.
¡«áEASI ¥§¡°´T ASLAN004 VS Dupilumab
82% vs 63%-67%, N=60:60 ,P=0.035
°ª¥Íª««ü¼Ð²Õ(TRAC > 1115pg /ml,¦n¨ìÃz! ,¥¼¨Ó°µÓ120¤H ,60:60 ©Mdupilumab PK,
P=0.035 ,¥NªíASLAN004 ©úÅãÀu©óDupilumab.
-------------------------------- Ãö©ó§C¥Íª««ü¼Ð²Õ,dupilumab 16¶gªvÀø«á¦³Àø®Ä!
Ó¤H»{¬°aslan004, 16¶gªvÀø,©ñ¤j¤H¼Æ20:20 ,¤´¦³¦¨¥\¾÷·|.¦Pdupilumab MOA,,¤£À³¦³¦p¦¹¤j®t²§.
¥»¦¸8¶gASLAN004ªvÀø«áEASI50 ¤w¹F67%.(6¤H) ¦A¥[9~16 ¶gªvÀø,¤´¦³¤j¾÷·|´£¤É¨ìEASI90/IGA 0,1.
¤UÓÁ{§É2b ¸Ñª¼,¤èª¾³Ì«á1/3 ¥Ø¼Ð¥«³õ¯à§_¸É¦^,ºÙ²Ä¤@.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/10/6 ¤U¤È 12:30:36
²Ä 4666 ½g¦^À³
|
To:«Ó°¶¤j
3¤ëªì¨º³õ´Á¤¤¼Æ¾Ú,¨S½æ¬O³Ì¤jªº¥¢»~~¦]·í®Éı±o1´Á´Á¶¡¼Æ¾ÚªºPȨS¨º»ò«n,ÁÙ¥i¥H¤ñ·Ó¦X¤@·sÃĪº¤Wº¦¼Ò¦¡,¨S·Q¨ì¥«³õ¦b1B®É¦p¦¹¬Ý«EASI-90¤ÎIGAªºPȨS¹L,PªÑ»ùÀWÀW¯}©³~~~«Ü¥i¯à¥«³õ¾÷ºc¬Ý¨ì¤F§ÚÌ©¿²¤ªº·ÀI,¥u§Æ±æ¥¼¨Ó¯à¥þ¨¦Ó°h°Ú !!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤W¤È 09:25:40
²Ä 4665 ½g¦^À³
|
Dupilumab ¤T´ÁCCL17/TRAC ³ø§i¡C
¦b¤T²Õ°ª¤¤§C16¶gªvÀø«á¥§¡°´T 63%-79% ¥NªíADªº±w¯f¾÷¨î¨Ã«D100%¡A¥Ñ¤uL4/IL13 ©ÒÁÍ°Ê¡C
REGN ´£¥XIL32¡A¦ý¥Ø«eµLÁ{§É资®Æ¥iµý©ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤W¤È 09:05:40
²Ä 4664 ½g¦^À³
|
9/27 1b ¸Ñª¼
RITT ASLAN004 16¤H¡A8¶gªvÀø¡C
°ò½uEASI 30.5 TRAC.>4000 pg/ml
§t3¦ì¤¤Â_¡A¤¤Â_²v3/16=19%
RITT ¥§¡°´T65% ¥Ñ©ódupilumab ¤T´Á¤¤断²v¶È7%.
RITT 16¡K¡K¤¤断°²³]¤U׬°1¤H¡A
16¡Ñ65%/14=74%
¥t¥~9-16¶gªvÀø¡A¦ô¥t¥~¼W¥[8%,74%+8%=82%ªº´Á±æÈ 16¶gªºRITT/REEPP¡C
Dupilumab 3´ÁÁ{§É¡A°ò½uCCL13/TRAC >1155pg/mlªº16¶gªvÀø«áEASI¥§¡°´T63%-67%.
¡«áEASI ¥§¡°´T ASLAN004 VS Dupilumab
82% vs 63%-67%
ASLAN004 22%-30% ¡AÀu©óDupilumab¡K¡K°ª¥Íª««ü¼Ð
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/10/6 ¤W¤È 08:53:03
²Ä 4663 ½g¦^À³
|
¥H¤U¬O 9/29 ªº¬Ýªk ¦Ü¤µ¤£ÅÜ
·|û¡G©ú¤Ñ¹L«á10151242 µoªí®É¶¡:2021/9/29 ¤W¤È 09:06:30²Ä 4559 ½g¦^À³ ¬Û«H¶R¨È·à±dªº¦U¦ì¤j¤j,¥¼¶}¼ú¤§«e³£¦bÀqÀq½Lºâ,§Úªº¦Ê¸U§ë¸ê¦b¤E¤ë¸Ñª¼«á·|½¦¨¦n´X¿·Ç³Æ¶R¨®¶R©Ð¤F,¦ý³o¦¸¶}¼úµ²ªG´N¬O¤£¦p¹w´Á,§Ú¥i¥H§i¶D¦U¦ì°ê¥~¦U§ë¸ê¶R®a¹Î¶¤¬O¤£¶R³æªº,¤]¤£n¬Û«H±Ë»ò§ë¸ê¾÷ºcµ¹¥Ø¼Ð»ù8¶ô¿ú(³o¨Ç³£¬O½æªÅªº¦nªB¤Í,§Aªº¿ú³£¬O³Q³o¨Ç½æªÅªÌÁȨ«)! °ê¥~ªº§ë¸ê¹Î¶¤¤£¬Oªxªx¤§½ú,I«á¬ã¨s¹Î¶¤ªº¥\¤O¤£ª¾¹D±j¹L³oÓª©ªº¬Y¨Ç¤ÀªR¼Æ¦Ê¿!¤]¤£·|¸ò§AºtÀ¸..¦n¼Æ¾Ú´N¬O¤j¶R,Äê¼Æ¾Ú´N¬O¤j½æ! ¦pªG¯uªº¹Ú¿ô¤F´NÅý¥L¿ô§a,¤d¸U¤£n¨I¾K¦b¹Ú¸Ìn¶}©l¾Ç·|±¹ï²{¹ê ! ¬üªÑºD©Ê¦pªG¤j¶^«áªº¹j¤ÑÁÙ¬O¤j¶^,¤§«áªº¼Æ©P±N·|«ù³Ð·s§C,¤£«H¶Ü ?11¤ë1¤é¤j®a¨ÓÅçÃÒ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/10/6 ¤W¤È 08:32:35
²Ä 4662 ½g¦^À³
|
to »Û£¤j: §Ú¬O¤U¸ü´I³~¤û¤û³nÅé¡A¥[¤J¦Û¿ïªÑ¬Ýªº¡A±¾¶R®É»ù¦ì¤ñ¸û¤Î®É¡A¤â¤WÁÙ¨S½æ¥X¹L¡K¡K¡K§¡»ù¤£§C(3.x)! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤W¤È 08:11:25
²Ä 4661 ½g¦^À³
|
www.morressier.com/article/biomarkers-ccl17tarc-total-ige-not-predict-clinical-response-dupilumab-atopic-dermatitis-ad-post-hoc-analysis-pooled-phase-3-data-solo-1--2/5d4980cb8fb7e44098e72cd2?
Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2) Submitted Sep 2, 2019
Jennifer D. Hamilton
Zhen ¡K¡K
结½×1..CCL17/TRAC ªº¥Íª«¼Ð»xª«®Ä»ù§C¡A°ò½uEASI´N§C¡C
¤Ï¤§°ª«h°ª¡C
CCL17/TRAC// ¤H¼Æ// °ò½u¥§¡EASI//ªvÀø«áEASI¥§¡°´T(¤ñ²v)//¥§¡°ªº¤À¼Æ¡C
Dupilumab 组 solo1 ¤pp 457. //32.4//70//22.6 <1115 154//24.1// 77.9// 19.5 1115~4300//153//32.4//67.4%//21.9 >4300//149//41.1/63.1%//26.2
Solo2 ¤pp 462 //32.5//70.7%//23,1 <1115 160//25.8//75.4%/19.1 1115~4300//147//31.2//66.4%//21.9 >4300//152//40.9//67.5%/27.5 ¡K¡K¡K¡K ¡K¡K¡K¡K ¹ï·Ó组 ¤pp460 //34.1//34.3%//11.5
143 //25.3//43.7%//11.5 157//32.4//23.3%//8.7 156//43.9//27.1%//11.5
结½×2 Dupilumab ªvÀø«áªºEASI¥§¡°´TÀø®Ä»P°ò½uCCL17/TRAC¥Íª««ü¼Ð®Ä»ù°ª§CµL¥¿¬ÛÃö¡C
¤T组CCL17/TRAC¤£¦P®Ä»ù¡A ¦P¼Ë¦³Àø®Ä¡C
¡K¡K¡K¡K 9/27 ASLAN004 1b 8¶g¡A¸Ñª¼¡C
6+3 ¤Hªº«D¶Ç²Î¤¤-««×±wªÌTRAC<1200pg/ml
¦ýªvÀø«á©M¹ï·ÓEAS¤u¥§¡°´T®t²§¤£¤j¡A¦b50%¥ª¥k¡C
²zÀ³°65%-70%.
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¥H¤UÓ¤H¬Ýªk ¦³«Ý2bÁ{§É ¤H¼Æ©Ô°ª¨ì60:60(§CCLL17/TRAC <1115¡A20:20¤H¡A¨Ó¦A¦¸ÅçÃÒ¡C
Y2b 16¶gªvÀø¡A©ñ¤j¨ì20:20¡A¤´µL®t²§¡A
则³Ìp3¡An¨Æ¥ý¥Î¥Íª««ü¼ÐCCL17/TRAC ¤À2组<1115 ¤À¤@组¡A¥t¤@组>1115®Ä»ù¡C
<1115 ©Û¶Ò¤H¼Æ¦û1/3, >1115 ©Û¶Ò¤H¼Æ¦û2/3
Y<1115,§C¥Íª««ü¼Ð®ÄªºªvÀø«áEASI«ü¼Ð©M¹ï·Ó组¤´µL®t²§¡A 则¥Ó½ÐÃÄ证¡A ¶È¥i½Ð>1115°ª®Ä»ù¥Íª««ü¼ÐªºÃÄ证¡A¦ûAD¥Ø¼Ð¥«³õ约2/3.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/6 ¤W¤È 07:23:54
²Ä 4660 ½g¦^À³
|
www.morressier.com/article/biomarkers-ccl17tarc-total-ige-not-predict-clinical-response-dupilumab-atopic-dermatitis-ad-post-hoc-analysis-pooled-phase-3-data-solo-1--2/5d4980cb8fb7e44098e72cd2?
Biomarkers CCL17/TARC and Total IgE Do Not Predict Clinical Response to Dupilumab in Atopic Dermatitis (AD): a Post hoc Analysis of Pooled Phase 3 Data (SOLO 1 & 2) Submitted Sep 2, 2019
Jennifer D. Hamilton
Zhen ¡K¡K
1.CCL17/TRAC ªº¥Íª«¼Ð»xª«®Ä»ù§C¡A°ò½uEASI´N§C¡C
¤Ï¤§°ª«h°ª¡C
CCL17 // °ò½u¥§¡EASI//¤H¼Æ//ªvÀø«áEASI¥§¡°´T(¤ñ²v//¥§¡°ªº¤À¼Æ¡C
Dupilumab 组 solo1/solo2 <=1115 24.1/25.8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/10/6 ¤W¤È 07:15:28
²Ä 4659 ½g¦^À³
|
¦N¦Ì¤j ½Ð°Ý¤@¤U n¥hþ¸Ì¬Ý ©e¶R/½æ±¾³æ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gonly10135877 |
µoªí®É¶¡:2021/10/5 ¤U¤È 11:22:44
²Ä 4658 ½g¦^À³
|
BTIG Research «¥Ó¤F¨È·à±d»sÃĪº«ù¦³µû¯Å¡C www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social&utm_campaign=SocialMedia |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/10/5 ¤U¤È 11:15:39
²Ä 4657 ½g¦^À³
|
©e¶R³æ©~µM¦³20k±¾¶R¡A¬O³QÀ£§C¶i³f¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/10/5 ¤U¤È 10:13:07
²Ä 4656 ½g¦^À³
|
ASLN004¤@´Á¸Ñª¼¥¿¦V,¦ý¥«³õ¨Ã¤£»{¦P,ªÑ»ù¤@ª½¶^
§ë¸ê¤Hnªº¤£¬O¥þ¨¦Ó°h
¦Ó¬O¤jµo§Q¥«¡A¤£µM´N·í¿úÅx¤j®ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/10/5 ¤U¤È 09:56:28
²Ä 4655 ½g¦^À³
|
¸¤H¤j©M§ÚÁÙ¦³©t¨à¤jÀ³¸Ó¬O¦P±èªº ¤]¬O§ë¸ê³Ì¤[ªº ¦b·à¤l¤@¨Ó¥x¤W¥«´N§ë¸ê¤F ²{¦b¯uªº¬O¯u¤ß´«µ´±¡ªü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/10/5 ¤U¤È 09:41:42
²Ä 4654 ½g¦^À³
|
²{¦b³oÓ»ù¦ì³o´X¦¸°Ñ¥[¶Ò¸êªº¾÷ºc¸òªÑªF¥þ³¡³£®M¦í¤F¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/10/5 ¤U¤È 09:35:37
²Ä 4653 ½g¦^À³
|
Äê¨ì¨S±Ï¡A¤î¤£¦í¶^¶Õ ·í§ë¸ê·à¤lªº¿ú¨S¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/10/5 ¤U¤È 09:26:11
²Ä 4652 ½g¦^À³
|
§Æ±æ¤µ±ß§O¦A¶^§Ö10%.......... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/4 ¤U¤È 10:36:35
²Ä 4651 ½g¦^À³
|
ITT ªº¤¤Â_²v ECZTRA 1 Tralo 51/601=8.5% ¹ï·Ó组18/197=9.1% ²Ä¤GÓTralo ¤T´ÁÁ{§É¤¤断²v www.clinicaltrials.gov/ct2/show/results/NCT03160885
ITT ªº¤¤Â_²v ECZTRA 3 Tralo 35/591=5.9% ¹ï·Ó组22/201=10.9% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/4 ¤U¤È 10:23:46
²Ä 4650 ½g¦^À³
|
www.clinicaltrials.gov/ct2/show/results/NCT03131648
ITT ªº¤¤Â_²v ECZTRA 1 Tralo 51/601=8.5% ¹ï·Ó组18/197=9.1%
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Dupilumab 3´Á ¤¤断²v7%-8%¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ASLAN004 1b RITT ¤¤断²v3/16=19%.
¬GEASI75=69%(§t¤¤断²v19%) YP3¡A¥i预´Á7%, RITT EASI75 ¥i´Á±æ¤W¤É¦Ü81%¡P
¤é«á |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/4 ¤U¤È 07:26:32
²Ä 4649 ½g¦^À³
|
Tralokinumab 2Ó ¤¤-««×AD ¤T´ÁÁ{§É³ø§i. ECZTRA 1 and ECZTRA 2 , N=199 :603//N=201:593
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
onlinelibrary.wiley.com/doi/10.1111/bjd.19574
¹Ï¤@,¤T´Á¥Dn«ü¼Ð:
0/2/4/6/8/10/12/14/16 ¶g, IGA 0,1 //EASI75 ¨«¶Õ¹Ï.
¦hŪ¬ÛÃöADÃĪ«Á{§É³ø§i¦³¯qªø§ë!
Tralokinumab 16¶gªvÀøAD ,EASI75/IGA,0,1 ¹êÅç²Õ/¹ï·Ó²Õ¤§¤ñȶȬùDupilumab ©M¹ï·Ó²Õ¤ñȤ@¥b.
Dupilumab ªºMOA(§@¥Î¾÷¨î)¥i¦P®Éªý¤îIL4/IL13°T®§¶Ç»¼. Tralokinumab ªºMOA(§@¥Î¾÷¨î)¥u¥iªý¤îIL13°T®§¶Ç»¼. µLªkªýÀÉIL4 °T®§¶Ç»¼. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/10/4 ¤W¤È 10:32:26
²Ä 4648 ½g¦^À³
|
·ÀIÁÙ¬OnºÞ±±¦n¡A¤£n¦³Åu¥ ªº¤ßºA¡AÆ[¹î®É¶¡©Ôªø ¦b¨Ì¦Û¤v¸êª÷¹B¥Îª¬ªp¤À§å¶R¶i ¤~¯à¨«¨ì³Ì²×½µPªº¾÷·| ¤jÀô¹Ò¦³ÂI¦MÀI¡AnÂÔ·V¤@ÂI |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/10/4 ¤W¤È 09:52:30
²Ä 4647 ½g¦^À³
|
§Æ±æ¦U¦ì¤j¤j,¹ï©ó§b·àªº¦nÃa¬Ýªk³£¯à¦b³oª©¦h¦hµoªí,³o¼Ëªº°Ñ¦Ò¤~§¹¾ã~~~·P®¦¤j®a¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2021/10/3 ¤U¤È 10:48:53
²Ä 4646 ½g¦^À³
|
¤Ñ©R¤j ¥xÁÞ¤j ©t¨àÃÄ ¤p§Ì¨ü¯qê²L ¦³¦U¦ì¤j¯u¦n |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/10/3 ¤U¤È 09:47:50
²Ä 4645 ½g¦^À³
|
ºë¸Û©Ò¦Üª÷¥Û¬°¶} ¤Ñ©R¤j´£¨Ñªº¸ê°T¥O¤H©ç®×¥sµ´
Dupilumab 1b ¥Dn«ü¼Ð¬Ò没¹LÃö, 没¤H´±»¡¥¦®t!
EASI 75 6% vs 29% , p=0.118 (¨S¹LÃö) ASLAN004 (¹LÃö) EASI 50 ¡]¹LÃö¡^
IGA 0,1 6% vs 12% , p=0.245(¨S¹LÃö) ASLAN004 (¨S¹LÃö)
Pruritus 18.6% vs 41.3%, p=.582 (¨S¹LÃö) ASLAN004 (¹LÃö)
©ñ¤¤ªø½u³¨¤j³½
²×©ó©ú¥Õ¬°¤°»ò¤½¥q°ª¼h»{¬°¼Æ¾Ú¬O¥¿±¦³¼ç¤Oªº¤jÃÄ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤U¤È 09:12:49
²Ä 4644 ½g¦^À³
|
¼ÒÀÀ Lebrikizumab 2b¼Æ¾Ú, ¦b²Ä8 ¶g,N=22:16®É, ¥þxÂШS!没¦³¤@¶µ«ü¼Ð¹LÃö.
¦ý¤H¼Æ¥[¤j¨ì75:52, 16 ¶gªºªvÀø«á, PȬÒ<0.001
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
p.25
Lebrikizumab 2b ,°²³] Á{§É¤H¼Æ N= 38, ¹ï·Ó²Õ16 VS Lebrikizumab 22
¹ï·Ó²Õ VS Lebrikizumab
----------P<0.05¹LÃö------
EASI 75 17% vs 46% , p=0.129 (¨S¹LÃö) IGA 0,1 5% vs 31% , p=0.117(¨S¹LÃö) EASI¥§¡°´T 31% VS 64% ,P=0.093(¨S¹LÃö)
Pruritus 22% vs 46%, p=.238 (¨S¹LÃö)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤U¤È 07:25:28
²Ä 4643 ½g¦^À³
|
Dupilumab 1b ¥Dn«ü¼Ð¬Ò没¹LÃö, 没¤H´±»¡¥¦®t!
EASI 75 6% vs 29% , p=0.118 (¨S¹LÃö) IGA 0,1 6% vs 12% , p=0.245(¨S¹LÃö) Pruritus 18.6% vs 41.3%, p=.582 (¨S¹LÃö)
www.nejm.org/doi/10.1056/NEJMoa1314768
Dupilumab ,1b*4¶gªvÀø*300mg,N=67 ¥Íª««ü¼ÐSerum = 6000 pg/ml(´X¥G¬°¶Ç²Î-««×AD±wªÌ) °ò½u:¹ï·Ó²Õ22.8 VS Dupilumab 30
¹ï·Ó²Õ VS. Dupilumab N=16 VS 51
-----------P<0.05¹LÃö------
EASI 50 19% vs 59% , p=0.012 EASI 75 6% vs 29% , p=0.118 (¨S¹LÃö) IGA 0,1 6% vs 12% , p=0.245(¨S¹LÃö) EASI¥§¡°´T 25.7% VS 57.7% ,P=0.049
Pruritus 18.6% vs 41.3%, p=.582 (¨S¹LÃö)
dupilumab ¶È¥|¶gªvÀø,没¹LÃöªº亖´Á16¶g¥Dn«ü¼Ð EASI75/IGA 0,`1 «Ü¥¿±`. ¤T´Á¤H¼Æ N=230:230
5-16¶gªºEASI75·|¤W¤É¨ì50%±q¥|¶g29% 5-16¶gªºIGA0,1·|¤W¤É¨ì38%±q¥|¶g12% 5-16¶gªºPruritus·|¤W¤É¨ì51%±q¥|¶g41.3% ------------------------------------------------------------
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8
www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤U¤È 03:29:39
²Ä 4642 ½g¦^À³
|
M0A«D±`¡B«D±`«n¡I
¤@¡B§ùÁת¢¡K¡KDupilumab ¤¤¤å¥é³æ¡C
§@¥Î¾÷Âà(M0A)
Dupilumab ¬O¤@ºØ IgG4 ¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤Wªº IL-4R£\ ¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T ®§¶Ç»¼¡C
Dupilumab ¥iÂǥѻP²Ä I Ãþ¨üÅéµ²¦X¦Ó§í¨î IL-4 °T®§¶Ç»¼¡A¥H¤ÎÂǥѻP²Ä II Ãþ¨ü Åéµ²¦X¦Ó¦P®É§í¨î IL-4 ¤Î IL-13 ¤§°T®§¶Ç»¼¡C
Dupilumab ªýÂ_¤¶¥Õ¯À-4 £\ ¨üÅé(IL-4R£\)¥i§í¨î IL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¤G¡BASLAN004 §@¥Î¾÷Âà(M0A)
ASLAN004 ¬O¤@ºØ IgG4 ¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-13 (IL-13)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤Wªº IL-13R£\1 ¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T ®§¶Ç»¼¡C ÂǥѻP²Ä II Ãþ结Åéµ²¦X¦Ó¦P®É§í¨î IL-4 ¤Î IL-13 ¤§°T®§¶Ç»¼¡C ASLAN004 ªýÂ_¤¶¥Õ¯À-13R£\1¨üÅé(IL-13R£\1)¥i§í¨î IL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¤T¡B¥H¤WDupilumab ¤ÎASLAN004 ,§í¨îÂI¤£¦P¡A¦ý¦³¦@¦P®ÄªG: Dupilumab ªýÂ_¤¶¥Õ¯À-4R£\¨üÅé(IL-4R£\) ¡A
ASLAN004 ªýÂ_¤¶¥Õ¯À-13R£\1¨üÅé(IL-13R£\1) ¡A
¦@¦P§í¨î®ÄªG:
¥i§í¨îIL-4 ¤Î IL-13 ²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥] ¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥Õ E (IgE)¡C
¥|¡BDupilumab ¥i»PIÃþ结Åé结¦X¡A¥i¯à²£¥Í结½¤ª¢°Æ§@¥Î¤§ì¦]¡C
¦ýASLAN004¨SIÃþ结Åé结¦X¡C
¤¡B ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action <¥H¤W¥]§t¤¶²ÐYASLAN004±µ¦XIL-13R£\1«á¦P结¦XR-4R£\®ÄªG>
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤W¤È 11:53:36
²Ä 4641 ½g¦^À³
|
¨ÖÁÊ»ù87¬ü¤¸/ªÑªºIMMU¡A¨ú±oBTD«á¡A ¡A¦]µu´ÁªÑ»ù¤j变°Ê¡A¥¼¨£¨äªø§ë»ùȦÓÂ÷³õªÌ¡A³Ì°ª¤ÖÁÈ37¿¡C ¤@¥Í¤§¾÷·|¤£¦h¡I
¡K¡K¡K¡K¡K¡K
m.investing.com/equities/immunomedics-historical-data
Immu ¤½¥q¡AIMMU132/ADC¡A³Q200»õ¬ü¤¸¨ÖÁÊ¡A¬ù87¬ü¤¸/ªÑ¡C
¤@ADCªv¥|´Á3½u«áBNTC¡A·sÃĤ½¥q¡A¥H2´ÁÁ{§É¥Ó½ÐÃĵý¡AÀòFDAªºBTD(¬ð¯}©ÊÀøªk)¡A
·í2016/¦~02¤ë ÀòBTD®ÉªÑ»ù¶È2.32¬ü¤¸/ªÑ¡A ´¿¸g±NIMMU132¥þ²y¾P°âÅv20¦h»õ¬ü¤¸±ÂÅv¥X¥h¡AªÑ»ùº¦¨ì25¬ü¤¸¡A«á¨Ó¤jªÑªF¶}°£CEO¡A¤£¦P·N±ÂÅv¦X约¡A¤½¥q³Ì«á2050¦~ÀòÃĵý¡AªÑ»ùº¦¨ì40¬ü¤¸¡A³Ì«á³Q¨ÖÁÊ»ù87¬ü¤¸¥ª¥k¡C
·sÃĤp¤½¥q´N¬O³Q¨ÖÁʪѻù³Ì°ª
¦b¬ü°ê¥Í§ÞªÑ«Ü¥¿±`. IMMU-132 °µ§¹ 2´Á,2016/02/06®³¨ìBTD,ªÑ»ù2.32¬ü¤¸/ªÑ
www.adcreview.com/news/breakthrough-therapy-designation-for-sacituzumab-govitecan-in-triple-negative-breast-cancer/
Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer 2016/02/06
Mar 15 3.83 4.11 4.36 3.64 18.00M -6.13% Apr 15 3.60 3.80 4.39 3.56 17.73M -6.01% May 15 3.86 3.62 4.39 3.62 15.98M 7.22% Jun 15 4.06 4.08 5.05 3.85 30.66M 5.18% Jul 15 2.05 4.07 4.32 1.83 51.47M -49.51% Aug 15 2.16 2.05 2.24 1.69 23.05M 5.37% Sep 15 1.72 2.21 2.62 1.50 19.19M -20.37% Oct 15 2.99 1.70 3.09 1.59 21.52M 73.84% Nov 15 3.29 3.01 3.40 2.73 16.66M 10.03% Dec 15 3.07 3.30 3.33 2.66 15.69M -6.69% Jan 16 1.88 2.96 3.02 1.68 15.78M -38.76% Feb 16 2.26 1.87 2.49 1.61 24.49M 20.21% Mar 16 2.50 2.27 2.80 2.21 18.32M 10.62% Apr 16 3.55 2.47 3.86 2.43 21.14M 42.00% May 16 4.84 3.63 4.88 3.41 33.26M 36.34% Jun 16 2.32 4.87 5.44 1.95 95.69M -52.07% Jul 16 2.65 2.33 2.75 2.09 24.27M 14.22% Aug 16 2.77 2.66 3.15 2.60 19.89M 4.53% Sep 16 3.25 2.78 3.43 2.60 18.13M 17.33% Oct 16 2.30 3.21 3.39 2.06 61.00M -29.23% Nov 16 3.22 2.34 3.59 2.02 38.49M 40.00% Dec 16 3.67 3.22 4.10 3.01 32.31M 13.98% Jan 17 4.50 3.65 4.82 3.30 45.15M 22.62% Feb 17 5.00 4.50 5.89 4.08 107.54M 11.11% Mar 17 6.47 5.07 7.15 4.73 90.95M 29.40% Apr 17 5.73 6.53 6.53 5.00 39.59M -11.44% May 17 7.55 5.73 7.97 5.22 87.11M 31.76% Jun 17 8.83 7.53 9.04 7.26 54.69M 16.95% Jul 17 8.56 8.84 9.51 8.10 35.31M -3.06% Aug 17 12.64 8.56 12.66 7.17 72.27M 47.66% Sep 17 13.98 12.90 14.19 10.85 55.97M 10.60% Oct 17 10.72 14.05 14.48 10.22 51.27M -23.32% Nov 17 10.86 10.76 12.83 9.72 66.46M 1.31% Dec 17 16.16 10.69 17.05 8.68 87.42M 48.80% Jan 18 16.67 16.29 18.93 15.20 56.04M 3.16% Feb 18 16.91 16.61 17.42 14.06 40.79M 1.44% Mar 18 14.61 16.92 18.08 14.27 43.78M -13.60% Apr 18 18.21 14.51 18.80 13.82 37.37M 24.64% May 18 22.06 18.11 23.18 17.58 50.37M 21.14% Jun 18 23.67 22.27 26.48 22.10 81.53M 7.30% Jul 18 23.93 23.37 27.33 22.30 37.85M 1.10% Aug 18 26.76 23.77 26.76 20.73 32.45M 11.83% Sep 18 20.83 26.85 26.99 20.06 28.86M -22.16% Oct 18 22.53 20.99 24.15 19.24 43.12M 8.16% Nov 18 20.09 22.71 24.99 16.80 47.75M -10.83% Dec 18 14.27 20.60 21.23 12.86 54.81M -28.97% Jan 19 14.79 14.10 18.61 11.55 104.35M 3.64% Feb 19 15.76 14.71 16.61 13.55 48.56M 6.56% Mar 19 19.21 15.90 19.27 15.90 49.22M 21.89% Apr 19 16.02 19.31 19.51 15.15 49.24M -16.61% May 19 13.07 16.05 16.26 13.01 67.04M -18.41% Jun 19 13.87 12.85 14.05 11.59 64.24M 6.12% Jul 19 14.75 14.27 15.63 13.73 35.38M 6.34% Aug 19 12.80 14.73 16.05 12.47 39.92M -13.22% Sep 19 13.26 12.66 17.55 12.05 59.23M 3.59% Oct 19 16.00 13.21 16.64 12.43 46.10M 20.66% Nov 19 18.78 15.99 19.52 15.90 32.81M 17.38% Dec 19 21.16 18.88 22.22 17.22 67.45M 12.67% Jan 20 18.57 21.26 21.32 17.18 37.22M -12.24% Feb 20 16.00 18.75 20.46 14.58 28.52M -13.84% Mar 20 13.48 16.18 17.27 9.18 65.99M -15.75% Apr 20 30.38 10.86 31.56 8.80 191.25M 125.37% May 20 33.59 29.88 35.47 29.69 65.47M 10.57% Jun 20 35.44 33.20 37.25 29.55 95.03M 5.51% Jul 20 42.23 35.79 44.48 35.62 51.78M 19.16% Aug 20 44.56 42.86 44.91 39.40 29.84M 5.52% Sep 20 85.03 44.54 86.91 37.85 180.01M 90.82% Oct 20 87.86 85.03 87.93 84.91 15.32M 3.33% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤W¤È 11:19:47
²Ä 4640 ½g¦^À³
|
¸¤H¤j¡A
1.¨ÖÁʪ̬ݪº©M¤@¯ë§ë¸êªÌ¤£¦P¡C
¨ÖÁʪÌn¬Ýªº¬OÀø®Ä¥D®_¯à¤O¡C
¥¼º¡¨¬¥«³õ¡A§A¯à¦û¾Ú¦h¤Ö¡H
ASLAN004 >Dupilumab
IGA¡A0/1 ¦ô64% vs 38% EASI,75 ,¦ô75% vs 50%
¦b¬Û¦P¤¤Â_²v¤ô·Ç 6-7% ¬Û¦P°ò½uIGA4=48%.¥§¡EASI32
2.¥«³õ¤WCNTB¤ÎRAPT
¥Î°ò½uIGA4=29%,¥§¡EASI23,¥Î轻¯gªº¨Ó¹êÅç¡AµM«á¥h¤ñ«¯gªºÀø®Ä¡A¬O¤W¥«¤½¥qªº©Ô°ªªÑ»ù¤âªk¡C
¥|¶g¡AIGA0.1¡A7¤H¡A¹F3/7¡A42%,(¤¤Â_²v 0%)
¨Ó¸¹ºÙ²Ä¤@¡C
Y16¶gªºªvÀø¡AIGA 0/1
ASLAN004 ¦ô¥iªv °ò½uEASI35¥H¤U100% Dupilumab ¦ô¥iªv°ò½uEASI28¥H¤U100% Lebrikizumab ¦ô¥iªvÀø°ò½uEASI25¥H¤U100% Tralo. ¦ô¥iªvÀø°ò½uEASI22.5¥H¤U100%
¨ÖÁʪ̥H¦¹¨Óp¹º¥«³õ¥¼¨Óº¯³z²v¡C
3.ªÑ»ù¼vÅT¦]¯À«D±`¦h¡C
¤½¥q¥»¦¸¤£¥]销¶Ò资¡A没©Ô°ªq»ùªº°Ê¾÷¡C ASLAN004 9/27资°T¤½¥¬´N¹w¦ô·|¶^¡C
¤½¥q¥D¤On¤£n©Ô»ù¡A¼vÅTªÑ»ù¦]¯À«Ü¤j¡C
ITT ¦³EASI90/IGA 0.1 ,p>0.05 , ¤@¯ë§ë¸ê¤H·|¦sºÃ«Ü¥¿±`¡C
1.¥L̤£ºÞ¤¤断²v¼vÅT3/22 2.¥L̤£ºÞ«D¶Ç²ÎAD¼vÅT6/22. 3.¥L̤£ºÞ¡A9-16¶gÁÙ·|¦¨ªø15%ªº谮¤O¡C
¥H¤W¤T¤j¦]¯À¼vÅT¥Dn«ü¼Ð55%¡C
¸¤H¤j¡A±z©|¥¼¤F¸ÑM0Aªº«n©Ê¡C
°ò¥»¨ÓASLAN004Àø®Ä±µªñDupilumab¡C
¨ä¥L¦]°Æ§@¥ÎÃö«Y¡A¨ÏASLAN004¥i¨Ï¥Î°ª¾¯¶q¡A©Ô¶}°ò½uEAS¤u29¥H¤Wªº¶ZÂ÷¡A¡K¡K1bÁ{§É¨ÑÄm¡C
©Ò¥H¤½¥q¤½§i Best -in-Class ¦Pµ¥级³Ì¨ÎÀø®Ä¡A³Ì¨Î¦w¥þ©Ê¡A¬O¦³¬ì¾Ç¤ÎÁ{§É¨Ì¾Ú¡C
ASLANªÑ»ù³Ì°ªÈ¦b³Q¨ÖÁʮɡC
50-70¬ü¤¸/ªÑ¡A¶]¤£±¼¡C
ªø§ëªÌ¬Ýªº´N¬OÁ{§É¼Æ¾Ú+¥«³õ渗³z²v¤§¦ôp¡C ¨ä¥L´N¬Oµ¥«Ý¡C
Àu©ó¨ú±o2±iBTD(¬ð¯}©ÊÀøªk)ªºDupilumab,
»ùÈ«D¤Z¡I
REGN¡A2011¦~11¤ë¨ú±o¡A黄´³³¡¯f变ªºÃÄ证¡A¤@¸ô±q70-º¦4¦~¨ì2015¦~dupilumab ¨ú±oBTD¡A500¦h¬ü¤¸¡C
Y¦b2009¦~§ë¸êREGN,ªÑ»ù¶È¤£¨ì20¬ü¤¸/ªÑ¡C
ªø§ë´A¤O¤Q¨¬¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/10/3 ¤W¤È 10:19:18
²Ä 4639 ½g¦^À³
|
To ¤Ñ©R¤j,
·Q½Ð±Ð¤@¤U¡A³o¦¸¤½¥qªº·s»D½Z»¡¼Æ¾Ú¬O¥¿¦Vªº¡A¥B¹ï©ó004¥¼¨Ó2´Á¶}µo«Ü¦³«H¤ß¡A¦ý¬O¬°¦ó¼Æ¾Ú¤½¥¬®É¡A¥«³õªº§ë¸ê¤H«o¤£¶R³æ©O? ¬O¦]¬°¼Æ¾Ú©M¤T¤ë¤½§iªº¬Û®t¤Ó»·¡A´NEASI-90¤ÎIGA³¡¤À°h¨B«Ü¦h¡AÁÙ¬O»{¬°004¦¹¦¸ªº¼Æ¾Ú¥i¥H¹w´Á2´Á¸ÕÅ礣·|¹LÃö©O? §_«h¬°¦óªÑ»ù·|³s¶^¤@Ó§«ô©O? ·Ó²z»¡¬üªÑ¤ÏÀ³®ø®§¡AÀ³¸Ó³£¬O¤@¤Ñ¤ÏÀ³§¹¤F¡A²{¦bªÑ»ù¦³§e²{¶W¶^²{¶H¡AÁÙ¬O¦]¬°¦b¿ï¾ÜÅv³¡¤À³\¦h§ë¸ê¤H§G¤F¤j³¡¦ìªºªÅ³æ¡A©Ò¥H·Qn¤@ªiÀò§Qº¡º¡¡A³y¦¨ªÑ»ù¤@ÂI¤ä¼µ³£¨S¦³¡A¸g¹L±zªº»¡©ú¡A±oª¾¦b¹ï·Ó²Õ9¤ë¤Î¤T¤ë³¡¤À¦³®tªºì¦]¡A¬O¦]¬°¤¤Â_²vªºÃö«Y¡A¥i¬O¤@¯ë§ë¸ê¤H¥i¯à¤£·|·Q¨º»ò¦h¡A¬Ý¨ìEASI-90©MIGA©M¤T¤ë¬Û®t¬Æ»·¡A´Nı±o2´Án¹LÃö«ÜÃø¡A©Ò¥H¤~·|©ß°âªÑ²¼¡A¦ý¬O±z¥ÎLebrikizumab¥¦¤G´Á¹LÃö¡A©Ò¥H±À´ú004¤G´Á¹F¼Ð¤]«Ü°ª¡A³oÂI¬O¦]¬°004©MLebrikizumab ¦³¬Û¦PªvÀø¤èªk¹ï©óAD¶Ü? ©Ò¥H¥i¥H¥Î±À¦ô¤è¦¡±À±o004 ¤]¥i¥H¹LÃö¡A¥u¬O¤£ª¾¬°¦ó³o¦¸§ë¸ê¤H¤ÏÀ³¨º»ò¤j¡A¬Æ¦Ü¤ñ¤§«e001¸Ñ¦£¥¢±Ñ³£¶^±o¦h¡A©ú©ú¼Æ¾Ú¾ãÅ饿¦V¡A¦ý¬O¦³¶µ«ü¼Ð°h¨B¡A«o¸¨±o¦p¦¹¤U³õ¡A¥i¯à¤j³¡¤À§ë¸ê¤H³£Ä±±o¹LÃö¬O¥¿±`§a¡A004¦¹¦¸¼Æ¾Ú¨S¦³¤ñ§ùÁת¢¨Óªº¦n¡A©Ò¥H¤~·|¥¢±æ¦a½æ¥X§a¡A¤£ª¾¤Ñ©R¤j¬Ýªk¬O¦p¦ó©O?
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/3 ¤W¤È 08:18:37
²Ä 4638 ½g¦^À³
|
ASLAN004 ³Q¨Ö»ùȦôp(¥«³õ¤ñ»ùªk) ¨ÌLebrikizumab¬°°ò¦¡C
LebriKizumabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
¨È·à«O¦³¦Pdupilumab ¸ô®|, ý³Ý/ªÍ³¡COPD/EOE.... ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ASLAN004Àø®ÄÀuDupilumab ¤@级¡C -------------------------------------------------- ¤C.¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù:
11/50*120*2=52.8»õ¬ü¤¸(¨È·à¿W±o)
Lebrikizumab AD³Q¨Ö»ù11»õ¬ü¤¸/2019¦~dupilumab 50»õ¬ü¤¸³Ì°ª¾P°â¹w´ú*2021¦~dupilumab 120»õ¬ü¤¸³Ì°ª¾P°â¹w´ú *2 ¿(¨ä¥L004¾AÀ³¯gý³Ý/COPD/EOE...¤ÎASLAN003»ùÈ.)
¡X¡X¦ô2022¦~¤U¥b¦~«áÀH®É¯àµo¥Í --¨ÖÁʪ̥t¶·¤ä¥ICSL¤W´å¦X¬ù. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/2 ¤U¤È 08:17:41
²Ä 4637 ½g¦^À³
|
¸¤H¤j¡A ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 P.14 ¸É¥R:
ASLAN004+Placebo site x <1200 pg/ml(8¤H)
ASLAN004+Placebo other site ¬ù4600 pg/ml(21¤H)--- B
Dupilumab p3 ¬ù6100 pg/ml(1379¤H)-----C
B/C=75% , ¥Nªí Dupilumab p3 ,1379¤H ªº¦¬®×¬Û¹ï©óASLAN004+Placebo other site ¬ù4600 pg/ml(21¤H)--- B
¬O§ó¯Â/§ó°ª¤ñ²vªº¶Ç²Îªº¤¤-««×AD±wªÌ.
------------------------------------------------------------------- ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3
³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.¤]¤£¬Odupilumab/lebrikizumab/tralo ¥Ø¼Ð±wªÌ,
¥L̥ΤWzÃÄ=¤£¥ÎÃÄ. 66% ·|¦Û¤v´î¨ìEASI50, ¥u¦³³æ¤@AD¯gª¬, «Ü¤jªº¥i¯à¶°¤¤¦b°ò½uEASI 20 ¥ª¥k.IGA3
¤£¬OII ª¢¯gªº¾÷Âà,
-------------------------------- µ²½×: 1.ASLAN004ªº³Ì¤jÄvª§¤O, ¦ô¦bAD°ò½u29~41 ¦³100%¥D®_¤O,¬° NO.1 Àø®Ä,µL¥LÃįà¤Î.
2.¤é«áP3 AD¦¬®×,¥§¡°ò½u¦bEASI31~32, ¦ôp°ò½uEASI 20¥ª¥k¤ñ²vÀ³«D±`¤Ö, ¼vÅT¥Dn«ü¼ÐEASI75/IGA0.1 ¥ç«Ü¤Ö. ¤j®a³£¤@¼Ë.
-------------------------------------------- 9/27,°ò½uEASI :
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/10/1 ¤U¤È 02:46:57²Ä 4628 ½g¦^À³ ¸¤H¤j¡A
Dupilumab¤ÎLebrikizumab 2/3´ÁÁ{§É¬Ò¥¼ç°£«D¶Ç²Î¤¤-««×AD±w¡A Ó¤H²qASLAN004 2b¡A¤£·|¥Î¥Íª«¼Ð»x¨Ó±Æ°£¡C
©ñ¤j¨ì3´ÁN=200:200¡A§ó¤£·|±Æ°£¡C
¤]³\16¶g·|¹FEASI75¡A©M¹ï·Ó¤@¼Ë¡A ¦b8¶gEASI50=66%¡P
II«¬ Recepter M0AªºªvÀø¦P¹ï·Ó组¡Adupilumab¤]¹J¦P¼Ë°ÝÃD¡CLebrikizumab,Tralo ¬Ò¤@¼Ë¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2021/10/2 ¤U¤È 02:32:51
²Ä 4636 ½g¦^À³
|
«Ü·PÁ¤ѩR¤j´£¨Ñ¸ê®Æ ¨M©wÄ~Äòµ¥«Ý¨ì¦¬ÁÊ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·RµL10148552 |
µoªí®É¶¡:2021/10/1 ¤U¤È 07:09:03
²Ä 4635 ½g¦^À³
|
·PÁ¤ѩR¤j´£¨Ñ¸ê®Æ!!! §Ú·|Ä~Äòµ¥«Ý¨ì¦¬ÁÊ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/10/1 ¤U¤È 06:21:42
²Ä 4634 ½g¦^À³
|
ÁÂÁ¤j®a ¦]¬°¦³§AÌ ·à¤l¸ô¤W¤£©t³æ §Ú¨M©w¦A¥[½X¼µ¤U¥h¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2021/10/1 ¤U¤È 05:40:31
²Ä 4633 ½g¦^À³
|
«D±`·PÁ¤ѩR¤j¡A¦h¤è¤Þ¥Î¸ê®Æ¡B¼Æ¾Ú¡A¨Ó¬°¤j®aÄÀºÃ¡B¸Ñ´b¡A Åý§Ú̦b¦Ñ·à³o±ø²î¤W¡AÁöµM¤@¸ô·n·n®Ì®Ì¡A«o¤]ÁÙ¯à°í«ù¨ì²{¦b¡A ¦ýÄ@¦Û¤v¯à½Õ¾ã¦n«ùªÑ¤ñ¨Ò¡A¸òÀH¨ì³Ì«á¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 03:52:15
²Ä 4632 ½g¦^À³
|
§ù¥²ª¢¡K¡K¤¤¤å¥é³æ
12.3 ÃÄ°Ê¾Ç §l¦¬ µ¹¤© dupilumab 600 mg ¥Ö¤Uª`®g (SC)°_©l¾¯¶q«á¤j¬ù 1 ¶g·|¹F¨ì³Ì°ª¥§¡¦å¤¤¿@«× (Cmax) ¡Ó¼Ð·Ç®t(SD)¬° 70.1¡Ó24.1 mcg/mL¡C
Dupilumab ¥ý§ë¤©°_©l¾¯¶q 600 mg¡A±µµÛµ¹¤© 300 mg ¨C¶g¤@¦¸(«Øijµ¹ÃÄÀW²vªº 2 ¿)©Î ¹j¶g¤@¦¸¡A¨äéwª¬ºA¿@«×·|¦b²Ä 16 ¶g«e¹F¨ì¡Cºî¦XÁ{§É¸ÕÅçµ²ªG¡A300 mg ¨C 2 ¶gµ¹ÃÄ ¤@¦¸ªºÃ©wª¬ºA³Ì§C¥§¡¿@«×¡Ó¼Ð·Ç®t(SD)¤§½d³ò¬° 73.3¡Ó40.0 mcg/mL~79.9¡Ó41.4 mcg/mL¡A 300 mg ¨C¶gµ¹ÃĤ@¦¸ªºÃ©wª¬ºA³Ì§C¥§¡¿@«×¡Ó¼Ð·Ç®t(SD) ¤§½d³ò¬° 173 ¡Ó 75.9 mcg/mL~193¡Ó77.0 mcg/mL¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
¨C¶g¤@°w¦å¤¤ªºdupilumab¿@«×¤ñ¨C¤G¶g¤@针¡A¥§¡°ª100-120mcg/ml.
¥´¦h¤F¾¯¶q¥u¬O¼W¥[¦å¤¤ÃĶq¡ADupilumab 16¶g¡A¨C¶g¤@°w¤Î¨C¤G¶g¤@°wªºÀø®Ä¦b¤T´ÁÁ{§É¬Û·í¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 03:26:44
²Ä 4631 ½g¦^À³
|
Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
Dupilumab 3´Á¡A§i¶D§A¤£·|¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkim10134548 |
µoªí®É¶¡:2021/10/1 ¤U¤È 03:19:29
²Ä 4630 ½g¦^À³
|
¤Ñ©R¤j¡A ½Ð°Ý±z ASLAN004¤@´ÁÁ{§É¬O¨C¶g¤@°w¡A¤G¡B¤T´ÁÁ{§É¦pªG³]p¬°¨â¶g¤Î¥|¶g¤@°w¡A ³o¼ËÀø®Ä¬O§_·|ÅÜ®t©Î°§C©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 02:58:50
²Ä 4629 ½g¦^À³
|
¥Ø«eASLAN004ªº¼Ú¬w区AD»ùÈ¡A¦ô¦Ü¤Ö¬O¥H¤ULebrikizumab,2019¦~2¤ëªº±ÂÅv»ùÈ3-3.5¿¡C
¡K¡K¡K¡K¡K¡K 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 02:46:57
²Ä 4628 ½g¦^À³
|
¸¤H¤j¡A
Dupilumab¤ÎLebrikizumab 2/3´ÁÁ{§É¬Ò¥¼ç°£«D¶Ç²Î¤¤-««×AD±w¡A Ó¤H²qASLAN004 2b¡A¤£·|¥Î¥Íª«¼Ð»x¨Ó±Æ°£¡C
©ñ¤j¨ì3´ÁN=200:200¡A§ó¤£·|±Æ°£¡C
¤]³\16¶g·|¹FEASI75¡A©M¹ï·Ó¤@¼Ë¡A ¦b8¶gEASI50=66%¡P
II«¬ Recepter M0AªºªvÀø¦P¹ï·Ó组¡Adupilumab¤]¹J¦P¼Ë°ÝÃD¡CLebrikizumab,Tralo ¬Ò¤@¼Ë¡C
¨ÖÁʤjÃļt¡A¤£¥Îµ¥2b¸Ñª¼¡A¥Ø«e资®Æ¤w¨¬°÷¤U诀µ¦¡C
¥H¤WÓ¤H¬Ýªk¡AASLSN004»ù¦ì50-60»õ¬ü¤¸ªº³Q¨ÖÁÊ»ùÈ¡C
´N©ñ¨ì«Å¥¬³Q¨Ö¡AªÑ»ù³Ì°ª¡C
§_«h´Nµ¥«D¬ü区±ÂÅvª÷额¥X²{¡C 2b¸Ñª¼¬O¥t¤@°ªûß¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/10/1 ¤U¤È 02:30:45
²Ä 4627 ½g¦^À³
|
To ¤Ñ©R¤j,
½Ð±Ð¤@¤U¡A¨º004¦pªG¬°¤F´£°ª¹LÃö¾÷²v¡A¬O§_¦b©Û¶Ò¯f±w®É¡A´Nn±Æ°£¤£¬O¤¤««×ªº±wªÌ¡A³o¼Ë¤~¥i¥HÅý004µo´§¤ñ¸û¤jªº¥\®Ä¡A¥t¥~½Ð±Ð¤@¤U¡A004¤G´Á¸ÕÅ窺´Á¤¤³ø§i¡A°²³]´Á¤¤¤½§iªº¼Æ¾Ú¤]¬O8¶g¥ª¥kªº¸ê®Æ¡A¨º³o¼Ë¼Æ¾Ú¬O§_·|¸ò³o¦¸®t¤£¦h¡A³o¼Ë¥«³õ¥i¯à¤]¤£·|¶R³æ¡A¦]¬°EASI-90¸òIGA¨S¦³²Îpªº·N¸q¡AÁÙ¬O´Á¤¤³ø§i¬O¬Ý§Oªº¦a¤è©O? ÁٽФ£§[»¡©ú¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 02:21:51
²Ä 4626 ½g¦^À³
|
¸¤H¤j¡A
´Á¥¼PK ´Á¤¤(¦P°ò¦EEPP)
9/27 ASLAN004 600mg²Õ ,¨Ï¥ÎRITT+EEPP«á ,N=13¤H EASI 50= 100%(RITT-EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)¤Îç°£«D¶Ç²ÎAD 6¤H) EASI 75= 85%(RITT-EEPP) EASI 90= 46%(RITT-EEPP) IGA 0,1= 54%(RITT-EEPP)
°ò½u:IGA3/IGA4=56%/44% --------------------------- 3/1, ´Á¤¤600mg+400mg (N=3+6=9¤H)¼Æ¦r ,EEPP
EASI 50= 89%(EEPP)(¤£¥]§t¥¼§¹¦¨29¤ÑªvÀø/µû¦ô//¤£§t¤¤Â_±wªÌ) EASI 75=67%(EEPP) EASI 90=56%(EEPP) IGA 0,1=22%(EEPP)
°ò½u:IGA3/IGA4=67%/33% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 02:09:06
²Ä 4625 ½g¦^À³
|
www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf P.20 Dupilumab 2Ó3 ´Á¡AN=212x2 ¹ï·Ó组¦b²Ä8¶gªºIGA0.1 约7%-8%.
¥»¦¸9/27 ¤½§G¹ï·Ó组IGA 0,1,2/13=15.4%¡A
´N·í§@¤p¼Ë¥»ªº²§±`È¡A¦h1¤H¡A¦h1/13=7.7%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤U¤È 01:56:58
²Ä 4624 ½g¦^À³
|
¸¤H¤j¡A
1.3¤ë1¤é ©Ò¤½§GªºÂ¡«á«ü¼Ð¤ñ²v¡A¤£§t¤¤Â_²v¡C 9¤ë27¤é¡A©Ò¤½§G¡«á«ü¼Ð¤ñ²v¡A§t3¦ìªvÀø¤¤断¡A¼vÅT²v3/16=19%¡C¡A RITT¡A¦A¤W19%¤~©M3¤ë¦P°ò¦EEPP¡C
2.¹ï·Ó组
«Øij¥h¬Ýdupilumab 3´Á¹ï·Ó组¡A
¤Îlebrikiumsb 2´Á¡A¨«¶Õ¹Ï¡C
©ñ¤j¶q¤ñ¸û·Ç¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/10/1 ¤U¤È 12:36:50
²Ä 4623 ½g¦^À³
|
To ¤Ñ©R¤j,
³o¦¸¤½§iªº¼Æ¾Ú¸ò¤W¦¸¤T¤ëªì¤½§iªº¼Æ¾Ú¬Û¤ñ¡A¥E¬Ý¤§¤U·|·Pı¦n¹³004¼Æ¾Ú«Ü®t¡A¨ä¤¤¦³¤@ÓÂI§Úı±o«Ü©_©Ç¡A·Qn½Ð±Ð¤Ñ©R¤j¡A¤T¤ëªì¤½§iªº¼Æ¾Ú: EASI-50¬°89%¡BEASI-75¬°67%¡BEASI-90¬°56%¡B IGA 0/1¬°22%¡A³o»P³o¦¸004ç°£±¼9¤H¤£¬O¤¤«¯gAD¯f±w¼Æ¾Ú¨Ó¤ñ¨Ã¨S¦³®t«Ü¦h¡ARITT¼Æ¾Ú¤À§O¬°: EASI-50¬°81%¡BEASI-75¬°69%¡BEASI-90¬°38%¡B IGA 0/1¬°44%¡A¨ä¤¤EASI-90¬O®t¤ñ¸û¦h¡A±q56%°¨ì38%¡AµM¦Ó IGA 0/1¬O¤W¤Éªº±q22%¤W¤É¨ì44%¡A©Ò¥H¨ä¹ê¨â¦¸¼Æ¾Ú¨Ã¨S¦³®t«Ü¦h¡C «e´£¬O¥HRITT¨Ó·í°ò·Ç¸ò¤T¤ë¤ñ¸û¡C
¦ý¬O©_©Çªº¬O¹ï·Ó²Õ¨Ï¥Î¦w¼¢¾¯ªº¯f±w¡A¥L̪º¼Æ¾Ú´N®t«Ü¦h¤F¡A¤T¤ë¨º¦¸¼Æ¾Ú¤À§O¬O : EASI-50¬°40%¡BEASI-75¬°0%¡BEASI-90¬°0%¡B IGA 0/1¬°0%¡A¦Ó³o¦¸¼Æ¾Ú§ÚÌÁÙ¬O¥ÎRITT¨Ó¬Ý¡A¹ï·Ó¼Æªº¼Æ¾Ú¤À§O¬O: EASI-50¬°31%¡BEASI-75¬°15%¡BEASI-90¬°15%¡B IGA 0/1¬°15%¡A¨â¦¸¬Û¤ñ¹ï·Ó²Õªº§ïµ½µ{«×©M¤W¦¸¬Û¤ñ¡A¨ä¤¤EASI-75¡BEASI-90¡BIGA 0/1¡A³o¤T¶µ¼Æ¾Ú³£¦n¤W¤£¤Ö¡A¨º¬O¬°¤°»ò©O? ¹ï·Ó²Õ¤£¬OÀ³¸Ó¨S¦³¥ÎÃÄ¡AÁÙ¬O³o¦¸¹ï·Ó²Õ¦³¥Î¨ä¥Lªº¤è¦¡ªvÀø¡A©M¤T¤ë¤½¥¬¨º¦¸ªº¹ï·Ó²Õ¤£¦P©O? §_«hn«ç¼Ë¸ÑŪ¨â¦¸¹ï·Ó²Õªº¼Æ¾Ú®t²§©O? ²¦³º®t²§ÆZ¤jªº¡A§í©Î¬O³o¦¸¹ï·Ó²Õ¬D¨ì¯f±w¦Û§Úªv¡¯à¤O¤ñ¤W¦¸¤T¤ë¨º¨Ç¹ï·Ó²Õªº¯f±w¨Óªº±j¡A©Ò¥H³o¦¸¤½§iªº¹ï·Ó²Õ¼Æ¾Ú¤~·|¨º»ò¦n¡A§_«h¦pªG¹ï·Ó²Õ¼Æ¾ÚÁÙ¬O¸ò¤W¦¸¤T¤ë¤@¼Ë¡A¨º³o¦¸ªºEASI-90¸ò IGA0/1ªºPȳ£¥i¥H¹F¼Ð¤F¡AÁٽФѩR¤j¯àÀ°¦£¸Ñ´b¤@¤U¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/10/1 ¤W¤È 11:04:35
²Ä 4622 ½g¦^À³
|
¬õ¹Ð¦³¹Ú¤j ¦pªG§Ú¬O¨È·à±d ¦pªG§Úªº³Ì²×½Lºâ¬On½æ±¼¨È·à±dªº¸Ü §Ú¤£·|§â003¤À¶}±ÂÅv
·í§Úªº004§ä¨ì¶R®a §Ú·|¤@¨Ö§â003µ¹¥´¥]¤@°_½æ¥X¥h
³o¼Ë¨ÖÁÊ»ù¤~·|°ª (¥H°Ó¤H¨¤«×) (ý³ÝªºÀø®Ä¥ç¦P) (¤@¶¡¤½¥q¥u¦³004©M003¡A§Ú¤j·§¤]²q¨ì¨È·à±d¬O·Ç³Æ½æ¤½¥q§a)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/10/1 ¤W¤È 10:09:48
²Ä 4621 ½g¦^À³
|
1 ´Á©M 2 ´ÁÁ{§É¬ã¨sªº 119 ¦W¨ü¸ÕªÌ¤¤¡AASLAN003 ¤w³QÃÒ©ú¹ï°ª¹F 400 ²@§J/¤Ñªº¾¯¶q¨ã¦³¨}¦nªº@¨ü©Ê¡A¨Ã¥B¾A¥Î©ó¨C¤é¤@¦¸ªº¤fªAµ¹ÃÄ¡C§Ú̥ثe¥¿¦bºV©w ASLAN003¦b¦Û¨§K¬Ì©Ê¯e¯f¤¤ªºÁ{§É¶}µop¹º¡C
°ò©ó¦´ÁÁ{§É¬ã¨s¤¤½T©wªº¯S²§©Ê¡B®Ä¤O©M¦³§Qªº¦w¥þ©Ê¯S¼x¡A§Ú̬۫H ASLAN003 ¥i¥H´£¨Ñ¤@¬yªº¼ç¤O§@¬°¦Û¨§K¬Ì©Ê¯e¯fªºªvÀø¤èªk¡A¨ä¤¤¦s¦b¹ï®t²§¤Æ©M¤è«KªºªvÀø¿ï¾Üªº¢¤Á»Ý¨D¡C
003¤@ª½¨S¦³»¡©ú¶i«×¡A¦pªG¯uªº¦³1,2´Áªº¶i«× ¦Ó¥B¥i³q¹L2b,¨º¤j¥i¥ý±N003±ÂÅv ¥i¼W¥[004±ÂÅvªº½Í§PÄw½X¡A©Î¥Î¨Ó ¶i¦æ004¤T´ÁÁ{§É¨Ï¥Î ¦U¦ì¤j¤j¥i¦³¬Ýªk |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 09:33:08
²Ä 4620 ½g¦^À³
|
CAN PEOPLE HAVE MORE THAN ONE TYPE 2 INFLAMMATORY DISEASE? It is not uncommon for people to have two or more type 2 inflammatory diseases, with different levels of severity. When a person has multiple coexisting type 2 inflammatory diseases, management is even more challenging. ¤H¥i¥H¶W¹L¤@Ó 2«¬ª¢¯g©Ê¯e¯f¡H ¤H֦̾³¨âºØ¥H¤WªºÃþ«¬¨Ã¤£¤Ö¨£ 2ºØª¢¯g©Ê¯e¯f¡AÄY«µ{«×¤£¦P¡C ¤@Ó¤H±w¦³¦hºØ¨Ã¦sªº2«¬ª¢¯g ¯e¯f¡AºÞ²z´N§ó¨ã¬D¾Ô©Ê¡C Up to 35% of people with asthma also have AD and up to 50% of those with AD have asthma
¦h¹F35¢Hªº¤H ÁÙ¦³ý³Ý ¦³AD¡Aª½¨ì ¦³50¢Hªº¤H AD¦³ ý³Ý
About 17% of people with CRSwNP also have AD and around 13% of those with AD have CRSwNP14,15
¬ù17¢H »P CRSwNP¤]¦³ AD©M ¤j¬ù13¢H ¨º¨Ç±w¦³ADªº¤H ¦³CRSwNP14,15
Around 50% of people with CRSwNP also have as thma and up to 45% of those with severe as thma have CRSwNP13,16
¤j¬ù50¢H ªº¤H CRSwNP¤]¦³ ý³Ý¤Î ¦³45¢Hªº¤H ÄY«ý³Ý¦³ CRSwNP
www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/about-us/5-TYNTK-TYPE-2-INFLAMMATION-EN_APPROVED.pdf
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 09:15:44
²Ä 4619 ½g¦^À³
|
www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf
Dupilumab ¼ÐÅÒÀÉ,
nªø§ëªÌ½Ð¦n¦n¬ã¨s©Ò.
p.20 ¦³ ¤T´Á¤¤-««×Á{ADªºIGA0,1 ®É¶¡ÁͶչÏ
DUPILUMAB 300mg q2w*16¶g SOLO1 ²Ä8¶g25%,²Ä16¶g40% SOLO2 ²Ä8¶g25%,²Ä16¶g36%
(©MLebrikizumab 2b ®t¤£¦h)
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
¦³x®É¶¡§Ç¦C,ªº¦U«ü¼ÐyÁÍ¶Õ ¹Ï,
0/4/8/12/16 ¶g. ¥idownload ÀÉ®×¥h¬Ý
Lebrikizumab 2b , Q2W*250MG ,
IGA 0,1 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.6%
EASI50 ²Ä8¶g¦b¬ù70%,²Ä16¶g81.0%
EASI75 ²Ä8¶g¦b¬ù44%,²Ä16¶g60.6%
EASI90 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.0%
-------------------------
2¶g¤@°wvs ¤@¶g°wªºEASIÁͶչÏ(Dupilumab 2Ó¤T´ÁÁ{§É)
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
--------------------------------------
·sÃħë¸ê«e´Á³Ì«nªºMOA!
·sÃħë¸ê«e´Á³Ì«nªºMOA!
·sÃħë¸ê«e´Á³Ì«nªºMOA!
ASLAN004ªºMOA ¦¦b2013 DUPILUMAB MOA ½T»{®É¤w³Q½T»{.
Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
¤Wz°Êµe¤w¥æ¥NASLAN004 IL13R ªº¥\¥Î¦PIL4R. ¥Î§ÜÅé«Ê¦í¨ä¤¤¥ô¤@Ó¬Ò¦P®É¥iªýÂ_IL4/IL13°T®§¶Ç»¼.
9/27 ¹êÅç²Õ¶È22Ó±wªÌ¸ê®Æ
¤¤Â_ 3¤H,«D¶Ç²ÎAD 6¤H, ¦Xp9¤H, ¼vÅT9/22=41%ªºÂ¡«áÀø®ÄEASI75/EASI90/IGA0,1 ¬Ò³Q¼vÅT.
¦A¨Ó¬Ý2b/p3
¤jÃļtnªº¸ê®Æ¤w¨¬°÷,¤U¨Mµ¦¨ÖÁʤF, ¦]¬°§Ú̦³¦ì¦n¦Ñ®vDupilumab/Lebrikizumab/Tralokinumab ¦b«e¤Þ¸ô.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:45:09
²Ä 4618 ½g¦^À³
|
1.CNTB ¬O¥t¤@ÓDupilumab ,¦b¬ü°ên¤W¥««Ü§xÃø,¥²±Á{±M§QÅv©x¥q,REGN ©x¥q¥²¥´. ª½¨ì2030¦~dupiiumab ¬ü°ê·sÃĤW¥«±M§Q12¦~¨ì´Á.
2.CNTB ¤ÎRAPT 1b ¬Ò¥Î°ò½u¥§¡EASI21~23,¦bÅã¥Ü¦nÀø®Ä.¬°¶Ò¸ê¤è«K.
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/9/16 ¤W¤È 10:06:22²Ä 4461 ½g¦^À³
RPT193 ªÑ»ùVS 1bÁ{§É³ø俈
www.marketwatch.com/investing/stock/rapt?mod=mw_quote_recentlyviewed 2021/06/14 µo§GRPT193 ¤fªAÃÄ 1b ADÁ{§É³ø§i»|(N=31 21/10), ªÑ»ù¤@¤Ñº¦120%(18~40),¥«È¥Ø«e11»õ¬ü¤¸. 37.5¬ü¤¸/ªÑ,¬ü°ê¤ÀªR®v¥Ø¼Ð»ù56¬ü¤¸(¥«È16.5»õ¬ü¤¸).
investors.rapt.com/static-files/32402320-09d1-43d2-9ef1-0dbd73d260b3
°ò½uBaseline Characteristics
PLACED//RPT193
EASI, Mean (Range) 21.07 (13.6-45.5) //18.49 (12-30) BSA, Mean (Range) 24.5 (10-61)// 23.3 (11-55) vIGA 3, n (%) 8 (80.0%)// 18 (85.7%) Peak NRS, Mean (Range)7.3 (3-10)// 6.9 (3-10) Peak NRS ≥4, n (%) 9 (90.0%)// 20 (95.2%)
Topline data from a placebo-controlled double-blinded Phase 1b trial examining 400 mg oral RPT193 as monotherapy for 4 weeks in 31 patients with moderate-to-severe atopic dermatitis* ¡V Efficacy: RPT193 demonstrates clear improvement over placebo on all key exploratory endpoints o At Day 29: EASI [36.3% vs. 17.0%], EASI-50 [42.9% vs. 10.0%], vIGA 0/1 [4.8% vs. 0.0%], and pruritis NRS-4 [45.0% vs. 22.2%] o Further improvement observed during the 2-week follow up period to Day 43: EASI [53.2% vs. 9.6%]†, EASI-50 [61.9% vs. 20.0%]†, and vIGA 0/1 [14.3% vs. 0.0%] ¡V Safety: Overall safety profile to date suggests a well-tolerated oral drug that would not require laboratory safety monitoring o No SAEs reported; all AEs reported were mild or moderate in intensity The clear clinical benefit combined with the favorable safety profile and oral convenience would support positioning ahead of approved and late-stage therapies A 16-week Phase 2b dose-ranging study in patients with moderate-to-severe AD will be initiated |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:34:21
²Ä 4617 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/4/7 ¤U¤È 08:02:41²Ä 4060 ½g¦^À³ www.connectbiopharm.com.cn/Templates/default/Common/images/EADV-2020-e-Poster-P0269-CBP201-AU002-FINAL-19-10-2020.pdf
CBP-201 1b 31¤HªºÁ{§É¸Ô²Ó¸ê®ÆÀÉ
baseline °ò缐¸ê®Æ¦p¤U
150mg//300mg///¹ï·Ó²Õ
1.EASI ¥§¡ 20.68//23.21///33.36( ¹êÅç²Õ¬O¹ï·Ó²Õªº69%,ASLAN004 1b¤Î Dupilumab ±µªñ33¥ª¥k)
2.IGA 0.1=4¤§¤ñ²v 0%//28.6%///25% (Dupilumab =50%¥ª¥k
µ²½× : ¨Ì°ò缐¦Ó¨¥¡ACBP-201 ¬O¤j¦hIGA0.1 =3ªº¤¤«×¤§¯gª¬¬°¥D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:21:53
²Ä 4616 ½g¦^À³
|
Âû¤ò³£©Þªº°®°®²b²bªº¤F ¦b¨Ó¬Ý¬On¤p¤õºC¿L¡AÁÙ¬On¤j¤õ§Öª£ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥¼¨Ó10138795 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:18:02
²Ä 4615 ½g¦^À³
|
ASLN(¤@´Á¸Ñª¼¦¨¥\) ¥Ø«eªÑ»ù1.78 CNTB(¤@´Á¸Ñª¼¦¨¥\) ¥Ø«eªÑ»ù 24.23 RAPT(¤@´Á¸Ñª¼¦¨¥\) ¥Ø«eªÑ»ù 31.05
¤Ñ©R¤j¬O¼Æ¾Ú¹F¤H¥i§_¤@¨ÖÀ°¤ñ¸û³o¤T®aªº¤@´Á¼Æ¾Ú©O?ÁÂÁÂ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:13:15
²Ä 4614 ½g¦^À³
|
ý³Ý¤T¤jÃÄ(dupilumab/lebrikizumab/traloªº¤T´ÁÁ{§É¸ê®Æ(¤¤¤åª©)
¦³¥Íª««ü¼Ð vs Àø®Ä
www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/10/1 ¤W¤È 08:07:59
²Ä 4613 ½g¦^À³
|
ÅÞ¿è«ä¦Ò¡G ©ú¦~6¤ëªº´Á¤¤³ø§i¦pªG¤£²z·Q¡Aª½±µ¥i¥HÃÒ©ú¨È·à±dGG¤F ¤£¥Î¥h´Á«Ý³Ñ¤Uªºý³Ý©M003¡C
¦ý¬O
©ú¦~6¤ëªº´Á¤¤³ø§i¦pªG¥¿¦V¡A©ú¦~©³¨È·à±d±N¡§³Q¢¡¨n§ä±ÂÅv¹ï¶H ¥þ²y«e5¤jÃļt¬Ý¨ì§ùÁת¢ªº¾P°âÃB«Ü¡K¡K ¤£·|¥h·m±ÂÅv¶Ü?
·íµM¤£·|¥h·m±ÂÅv
ª½±µ¨Ö¤F¨È·à±dÁÙ¤ñ¸û§Ö
©Ò¥H©ú¦~6¤ëªº´Á¤¤³ø§iµ²ªG¤~¬OÃöÁä¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 07:40:39
²Ä 4612 ½g¦^À³
|
°ò½uªº¶Ý»Ä©Ê²É²ÓM¤ô¥¦bý³Ý§êºtªº¨¤¦â§ó«¡C
¦b¥æFDA dupilumab label Àɤ¤¡C
°ò½uªº¶Ý»Ä©Ê²É细M¿@«×·U°ªÀø®Ä·U¦n¡C
§C©ó150 细M/cum,©M¹ï·Ó组Àø®ÄµL²§¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 06:40:17
²Ä 4611 ½g¦^À³
|
P.14
Patient history and biomarkers not consistent with typical moderate-to- severe AD patient population: • All patients1 at Site X had TARC levels below 1,200 pg/ml • 89% of patients at Site X had no allergic co-morbidities (compared to 13% at other sites) • Baseline eosinophil levels at Site X around an order of magnitude lower than other sites and other comparable AD studies ªÌ¯f¥v©M¥Íª«¼Ð»xª«¤£»P¨å«¬ªº¤¤¦Ü ««× AD ±wªÌ¤H¸s¬Û¦P¡G
• ¯¸ÂI X ªº©Ò¦³±wªÌ 1 ³£¦³ TARC(¥Íª«¼Ð»x) ¤ô¥ §C©ó 1,200 pg/ml • ¯¸ÂI X 89% ªº±wªÌ¨S¦³ ¹L±Ó©Ê¦X¨Ö¯g¡]»P13% ¦b¨ä¥L¦¬®×¤¤¤ß¡^ • ¯¸ÂI X ªº°ò½u¶Ý»Ä©Ê²É²ÓM¤ô¥ ¤j¬ù§C¤@Ӽƶq¯Å ¤ñ¨ä¥L¦¬®×¤¤¤ß©M¨ä¥L¥i¤ñAD¬ã¨s
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/10/1 ¤W¤È 06:25:19
²Ä 4610 ½g¦^À³
|
¦³¥Íª«¼Ð»x¤@¤Á¦n¿ì¨Æ¡I ³o¤~¬O¬ì¾Ç¡I
¦X¤@ªºFB825¾Ú¤½¥qºÙ¡A¤w§ä¥X¥Íª«¼Ð»x(¤£¬O²Ä¤@¥NªºIGg)¡A ¥i´£¤ÉÀø®Ä¡A¥u¬OnÄ묹¤@¨Ç«D¥Íª«¼Ð»xªº¥«³õ¡C
ç°£9¤Hx¦¬®×¤¤¤ß¡A«D¶Ç²Î¤¤-««×AD±wªÌ
89% (8/9)µLADªº¨ä¥L¨Öµo¯g¡A¦pµLýºÝ¡BEOE¡K¡K¡K¡K ¦ý¨ä¥L¦¬®×¤¤¤ß¦¹Ãþ¤ñ²v¶È13%¡C¡A¤@¯ëII«¬ª¢¯g¤¤-««×±w¯f20¦h¦~¡A¤@¯ë¦³AD´N·|¦³°ª¤ñ²vªº¦pý³Ý¡BEOE¡B¡K¡Kµ¥¨Öµo¯g¡ADupilumab ¤x¥X¹L³ø§i¡C
¥Íª«¼Ð»xª«¥ç¿@«×«D±`§C1200³æ¦ì¡A ASLAN004¨ä¥L¦¬®×¤¤¤ß¤ÎDupilumab¦b4000-5000³æ¦ì
¥H¤W¨Ó¦Û9/27¸Ñª¼³ø§i¡A ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K 1.¤w¸g¦³Dupiluman/Lebrikizum/Taol¤T¤jÃÄ©MASLAN004 ¦P¾÷Âà(M0A)¡A¥L̤]¹J¦¹°ÝÃD¡ADupilumab¯d¤U¦U¶¥Á{§Éªº测ÅçÈ¡C 2.¬Ý°_¨Ó«D¶Ç²ÎAD¯f±w¤ñ²v¡A¤j约13%-15%¥ª¥k¡A¦³2/3¡«á¥i¹FEASI 50,¹ï·ÓEASI901/3, ¦]¦¹¬ì¾Ç©eû·|¨Sç°£¨ä¥L13%«D¶Ç统AD±wªÌ¡C
结½×¡Adupilumab¦¨¥\ªº¸ô径´N¬OASLAN004ªº¸ô¡C
¤j®a¹J¨ìªº°ÝÃD³£¤@¼Ë¡A§O¤HY¤£ºÞ¥L¡A©ñ¤j¦¬®×¤H¼Æ¡A¦ÛµM¸Ñ¨M¡C
¤]³\«D¶Ç²Î¤¤-««×ADªº¤ñ²vªñ15%¡A ³o¬O¡«á«ü¼ÐEASI50©MEASI75ªº®t²§«¤j¦]¯À Dupilumab ¤T´Á EASI50=65% EASI75=50%¡P
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/30 ¤U¤È 11:09:34
²Ä 4609 ½g¦^À³
|
»¡¶BÄF¶°¹Î¤]¤Ó¹L ÁöµM·à¤l®`§Ú½ß¿ú¡A¦ý§ÚÁÙ¬OnÀ°¥¦»¡Ó¸Ü ½T¹ê·à¤lGÀùÁx¹DÀù³sÄò¸Ñª¼¥¢±Ñ ¦ý¥H³o»ò¤pªº¤½¥q¸g¾ú¨â¦¸«¤j¥¢±ÑÁÙ¬O¯à¼µ¦íÄ~Äò¾Ä°« ³o¤w¸g¬O¤£Â²³æ¤F ¯S§O¥¦¦]¬°¥xªÑ¨î«×¤£±o¤£¤U¥«®É¡A¤]¨S¦³©ñ±ó¥xÆW§ë¸êªÌ µ¹¤F§ÚÌÂà´«ADRªº¾÷·| ¦pªG¥¦¬O¶BÄF¶°¹Î¡A¤j¥i¥H¤£ºÞª½±µ¨«¤H
¥u¯à»¡·sÃĬãµo½T¹ê½ÆÂø½T¹ê¤£®e©ö §ë¸ê·à¤l³o±ø¸ô¤]¬O¦Û¤v¿ïªº ¥u§Æ±æ·à¤lþ¤Ñ¯u¯à³Â³¶ÅÜ»ñ°Ä¦³¦nªºµ²ªG ·íµM§Ú¤]¤w¦³¥´¤ôº}ªº·Ç³Æ ¤j®a§O¦]¬°§ë¸ê¼vÅT¥Í¬¡¡A¤@°_¥[ªo§a §Ú·|µ¥«Ýµ²ªG¥XÄl |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2021/9/30 ¤U¤È 10:43:52
²Ä 4608 ½g¦^À³
|
¤Ñ©R¤j¤j¡A §Úı±o¤£¬O¹B®ð¤£¦n ¥i¯à¬O¬ãµo¯à¤O¤£¦n¡A¥B§Þ¤£¦p¤H GÀùÁx¹DÀù¨ÅÀù¡A¸Ñª¼¨S¤@¦¸¦¨¥\ §Úı±o³o®a¤½¥q¸Û«H¦³°ÝÃD¡A¤]¥i¯à¬O¶BÄF¶°¹Î ±q·s¥[©YÄF¨ì¥xÆW¡A3¦~ÄF¨ì¤U¥«¡A¦AÄF¥h¬ü°ê
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 09:24:31
²Ä 4607 ½g¦^À³
|
¥»¨Ó¥Î¨Ó¥[¤Àªº»´¤¤¯gAD(°ò½uEASIV19),Åܦ¨ITT t¤À-----¹B®ð¯uªº¤£¦n.
¼ÒÀÀITT ----¦pªG¬O6¤HÅܬ°¶Ç²ÎAD-»´¤¤¯g(°ò½uEASI 19 ¥H¤U ) ,ASLAN004 600mg ²Õ,
¦pªG¬O¶Ç²ÎAD-»´¤¤¯g EASI 19 ¥H¤UASLAN004¯à¤O
600mg²Õ 22¤H(¥]§t3¤H¤¤Â_)---¼ÒÀÀITT EASI50 86%(2+17/22) EASI75 77%(6+11/22) EASI90 54%(6+6/22) IGA 0,1 59%(6¡Ï7/22)
¥§¡EASI°´T72%
-----------------------------------
¦pªG¬O¶Ç²ÎAD-»´¤¤¯g EASI 19 ¥H¤U
ASLAN004¯à¤O
600mg²Õ 6¤H IGA 0,1 100%(6/6) EASI50 100%(6/6) EASI75 100%(6/6) EASI90 100%(6/6) ¥§¡EASIN°´T90%
¥»¨Ó¥Î¨Ó¥[¤Àªº»´¤¤¯g,Åܦ¨ITTt¤À-----¹B®ð¯uªº¤£¦n.
---------------------------- ³Qç°£«D¶Ç²ÎAD 9¤H¡«á«ü¼Ð
(°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3)
600mg²Õ 6¤H IGA 0,1 0%(0/6) EASI50 67%(4/6) EASI75 0%(0/6) EASI90 0%(0/6) ¥§¡EASIN°´T50%
¹ï·Ó²Õ 3¤H IGA 0,1 0%(0/3) EASI50 67%(2/3) EASI75 0%(0/3) EASI90 33%(1/3) ¥§¡EASIN°´T54%
---------------------------------------------------------- ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ (°ò½u¥§¡EASI 19.9 vs 18.2 ,IGA3)
³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
°ò½uEASI:
600mg vs ¹ï·Ó²Õ ITT 27.6 vs 29 RITT 30.5 vs 31.5 ç°£9¤H 19.9 vs 18.2
°ò½uIGA3/IGA4
ITT 68%/32% vs 67%/33% RITT 56%/44% vs 54%/46% ç°£9¤H 100%/0% vs 100%/0%
µ²½×: ³Qç°£«D¶Ç²Î-¤¤««×AD,°ò½u¥Ü ¬Ò¬°»´¤¤«×AD±wªÌ,³o¤£¬OASLAN004 ¥Ø¼Ð±wªÌ.ç°£ªº¦n!
³Qç°£9¤H.
°ò½u¥§¡EASI 19.9 vs 18.2
°ò½u100%¬Ò¬OIGA 3
P.15
ir.aslanpharma.com/static-files/da4bc98e-9b9d-4add-8d6b-b66b427f76e8 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/30 ¤U¤È 08:20:48
²Ä 4606 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 06:51:16
²Ä 4605 ½g¦^À³
|
¥xÁÞ¤j,
www.marketwatch.com/investing/stock/asln/options?mod=mw_quote_tab
1.¨C¤ë15¤éµ²ºâ, ¥Ø«e¨C¤ë¬Ò¦³¶}½L.¤w¶}¨ì©ú¦~¥|¤ë.
2.¨C©u§ó·s¤@¦¸¾÷ºc«ùªÑ©ú²Ó.
whalewisdom.com/stock/asln |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/9/30 ¤U¤È 06:40:31
²Ä 4604 ½g¦^À³
|
¤½¥q¥i¯à¥i¥HÀË°Q§ï¶i¦a¤è 1¦¬®×±ø¥ó¬ì¾Ç¤Æ 2ÃĮľ÷¨î¦A²`¤J±´°Q 3¬I¥´¶¡¹j»P¾¯¶q 4Æ[¹î®É¶¡¬O§_¨¬°÷ 5Âå®v¨Ì¾Ú¦¬®×±ø¥ó¦¬®× 6ª`·N¬Ì±¡¬O§_¼vÅT°lÂܳy¦¨³¡¤À¨ü¸Õ¬y¥¢ 7¨C²Õ¦¬®×Àø®Ä¹F¼Ð³Ì¤Ö¤H¼Æ¹w¦ô
¤Gb Á{§É¤À¤²Õ¦@¦¬300¤H*16¶gªvÀø §Æ±æ¸u¥ô³o¨â¦ì¬ì¾ÇÅU°Ý¯à¨ó§UASLAN004 ¶}µo¦¨¥\
1.300mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3000mg 2.400mg/Q2W(¨C¤G¶g¤@°w/²Ä¤@¶g&²Ä¤G¶g¦U600mg), ¦Xp3600mg 3.400mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3000mg 4.600mg/Q4W(¨C¥|¶g¤@°w/²Ä¤@,¤G,¤T¶g¦U600mg), ¦Xp3600mg 5.¹ï·Ó²Õ
¸u¥ô¨â¦ì¬ì¾ÇÅU°Ý²¤¶ Lawrence Eichenfield ³Õ¤h¬O¸t¦a¨Èô¹p}¨àµ£Âå°|¨à¬ì©M«C¤Ö¦~¥Ö½§¬ì¥D¥ô¡A¥Ö½§¬ì©M¨à¬ì¯S¸u±Ð±ÂÝ¥Ö½§¬ì°Æ¥D¥ô ¥[¦{¤j¾Ç¸t¦a¨Èô¤À®ÕÂå¾Ç°|¡C Eichenfield ³Õ¤h´¿¾á¥ô¸Ó¬ã¨sªº¥Dn§@ªÌ©MÁp¦X¥D®u,¬ü°ê¥Ö½§¯f¾Ç·|¯SÀ³©Ê¥Öª¢«ü«n©eû·|©eû¡A¨Ã¾á¥ôªÀ½×¦hÓ¨ä¥L´Á¥Z©M´Á¥Zªº¸³¨Æ·|¡C°£¤FÂ×´IªºÁ{§É¸gÅç¥~¡A¥LÁÙ¼¶¼g¤F¶W¹L 400 ½gÃö©óª¢¯g©Ê¥Ö½§¯fªº¥Xª©ª«¡C¡§§Ú«Ü°ª¿³¥[¤J ASLAN ¬ì¾ÇÅU°Ý©eû·|ªº¥D®u¡A¨Ã¨ó§UÂåÀø¹Î¶¤±À¶i¨ä¥Dn¸ê²£ ASLAN004 ¥Î©ó¯SÀ³©Ê¥Öª¢©M¹L±Ó©Ê¯e¯fªº¶}µo¡¨¡AEichenfield ³Õ¤h»¡²§¦ì©Ê¥Öª¢¬O¤@ºØ¼vÅT¥þ²y¼Æ¦Ê¸U¤Hªº¯e¯f¡A¨ä»Ý¨D¥¼±o¨ìº¡¨¬¡A¾¨ºÞ¹L¥h¤¦~Å@²z¼Ð·Ç¦³©Ò¶i¨B¡C±wªÌ©MÂå¥ÍÀ³¸Ó°Ï§O¹ï«Ý¥i¥H§ïµ½¥Í¬¡½è¶qªºªvÀø¤èªk¡C§Ú´Á«Ý¦bÃöÁä®É¨è»P ASLAN ¹Î¶¤¦X§@ ASLAN004 ªºµo®i¡A§Ú«Ü°ª¿³¥[¤J³oÓ¥Rº¡¬¡¤OªºÅU°Ý©eû·|
®J¨½§J¡P¨¯´¶´Ë³Õ¤h¬O«X°Ç©£¦{½Ã¥Í»P°·±d¤¤¤ßªºÂå¾Ç¥Ö½§¯f¾Ç±Ð±Â©MÁ{§É¬ã¨s¥D¥ô¡C¬ì¾Ç¤j¾ÇÁ{§É¬ã¨s¤¤¤ß¡C¥L¬O¬ü°êÀã¯l¨ó·| (NEA) ¬ã¨s¿Ô¸ß¥D®u,©eû·|©M NEA ¬ì¾Ç©MÂå¾Ç¿Ô¸ß©eû·|ªº¦¨û¡A¼¶¼g¤F 200 ¦h½gÃö©óª¢¯g©Ê¥Ö½§¯fªº¥Xª©ª«¡C
½Ð°Ý±áÄf¤j1 ¤Ñ©R¤j 2
1ÅvÃÒ¨ì´Á¤@¯ë»Ý¦h¤[?
2¦³9¤ë¥÷ASLN ADR ¸³ºÊ«ùªÑ»P¤Q¤jªÑªF¸ê°T ? ¤ñ¸û¤@¤U9¤ë»P10¤ë¸³ºÊ«ùªÑ»P¤Q¤jªÑªF¸ê°T ¬Ý¬Ý¦³¨S¦³¼W´î? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2021/9/30 ¤U¤È 05:14:27
²Ä 4603 ½g¦^À³
|
´N¦³»¡¹L ¤@°ï¤H¶RÅvÃÒ¡A¦pªG½Ä¤W¥h¡A¨é°Ón½ß¤@°ï¿ú¡Aµ¥ÅvÃÒ¨ì´ÁªÑ»ù´N¦ÛµM¤W¥h¤F. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 04:22:43
²Ä 4602 ½g¦^À³
|
¥Ø«eªÑªFµ²ºc¥H¹ï¨R°òª÷¬°¥D.
¹ï¨R°òª÷µu½u«D±`¼F®`,¿ú¤S¦h!¦hªÅ¬Ò°µ!¦³´Á³fÂù¦V¥i¾Þ§@.
ASLN ªÑ¥»¤p,©ö³Q¾ÞÁa!
¾Þ§@µu½un¤p¤ß!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/9/30 ¤U¤È 03:36:00
²Ä 4601 ½g¦^À³
|
³oÃä¤]¤£¬O¤@¨¥°ó¡A¤£¦p... ¤j®a§V¤O·j´M¡A§â¹ï¤½¥q¡B¹ïASLAN004¡B¹ïADÃĪ«µo®iµ¥¦³©ÒºÃ¼{ªº ¥þ³¡¶}©ñ´£¥X¨Ó¡A¤@°_°Q½×
¤£µM¡AÁÙ¦³¦nªøªº®É¶¡nµ¥«Ý...¤]µL²á
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/9/30 ¤U¤È 02:58:30
²Ä 4600 ½g¦^À³
|
°Ý¤@¤U¦Û¤v
§Ú¥i¥H©êASLAN004 ¨ì2022¦~6¤ë´Á¤¤³ø§i¥X¨Ó?? ºâºâ´N³Ñ9Ó¤ë®É¶¡
2022¦~©³ 2bÁ{§É¸Ñª¼¼Æ¾Ú¥X¨Ó«e ¨È·à±d´N¡¨³Q¢¡¨n§ä¼t°Ó±ÂÅv¡K¡K¡K. ºâºâ´N³Ñ15Ó¤ë®É¶¡.
(¤£¥Î¹³IMMU¤@¼Ë 2016¦~~2020¦~)
¦U¦ì¤j¤j¦A¼µ¤@¤U§a. (¤Ï¥¿ªÑ»ù³£¡K¡K¡K)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 02:11:57
²Ä 4599 ½g¦^À³
|
°Ý¤@¤U¦Û¤v
§Ú¥i¥H©êREGN 2005¦~¨ì2021¦~? finance.yahoo.com/quote/REGN/
2005¦~6¬ü¤¸/ªÑ(ªk°êÁÉ¿Õµá¤JªÑ20%)
§Ú¥i¥H©êIMMU 2016¦~~2020¦~? m.investing.com/equities/immunomedics-historical-data
2020¦~Immu ¤½¥q¡AIMMU132/ADC¡A³Q200»õ¬ü¤¸¨ÖÁÊ¡A¬ù87¬ü¤¸/ªÑ¡C 2016/02 2.36¬ü¤¸
©Ò¨Ì¾Ú BTD+¼ç¦b¥«³õ...????
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 01:56:22
²Ä 4598 ½g¦^À³
|
ªø§ë¤~¬O¤j´TÀò§Qªº¸ô®|ÁÉ
¤ñ¨ú±o¤G±iBTD ªºDUPILUMAB §ó°ª¤@¯ÅASLAN004, ¬Û¦P¯àªýIL4/IL13°T®§¶Ç»¼ MOA,§ó°Æ§@¥Î§C,§ó¦w¥þ.
ASLAN004 EASI75 75% vs dupilumab 50% ASLAN004 EASI90 62% vs dupilumab36% ASLAN004 IGA0,1 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô
------------------------------- Dupilumab 2015¦~¨ú±oFDA ªº ¦¨¦~¤HAD BTD(¬ð¯}©ÊÀøªk) Dupilumab 20202¦~9¤ë¨ú±oFDA ªº 12·³¥H¤W,ªº, BTD(¬ð¯}©ÊÀøªk)-------²Ä¤G±iBTD
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
pipelinereview.com/index.php/2020091475851/Antibodies/FDA-Grants-Dupixent-dupilumab-Breakthrough-Therapy-Designation-for-Eosinophilic-Esophagitis.html
¤¤断²v׬°1/16=6.3%(±µªñDupilumab 3´Áq2w¤¤断²v7%)
¼ÒÀÀITT¡A¡«á«ü¼Ð¦p¤U
ASLAN004 600²Õ ,¨Ï¥ÎRITT+REEPP«á¡A¤¤Â_²v6.3% EASI 50 94%(RITT-REEPP) EASI 75 79%RITT-REEPP) EASI 90 40%(RITT-REEPP) IGA 0,1 48%(RITT-REEPP)
¥¼¨Ó16¶gªºªvÀø(ITT) ASLAN004 ¡«áIGA 0,1 /EASI90 ±N©Ô¤ÉÂ÷EASI75¤ñ²v79%®t12%/14%ªº68%/66% ¡K¡K¡K¡K¡K¡K IGA4 44%(°ò½u)¤W¤É¦Ü48%(¦PDupilumab ¤T´Á) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K EASI75 ¦ô°¦Ü75% vs dupilumab 50% EAS¤u90 62% vs dupilumab36% IGA0,1 64% vs dupilumab 38%
¥H¤W¬OASLAN004 ¥¼¨Ó2b/P3 ªº³Ì·s预¦ô |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2021/9/30 ¤U¤È 01:31:17
²Ä 4597 ½g¦^À³
|
To:¬õ¹Ð¤j
·sÃÄ´N¬O½ä¤@§â¨S¿ù,¦ý¤½¥q¬£n¦³§@¦hªº·NÄ@°Ú!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/30 ¤U¤È 12:51:31
²Ä 4596 ½g¦^À³
|
¥Ñ¦¹ÃÒ©ú ªÑ»ù¥Ã»·©¹§A·Q¤£¨ìªº¦a¤è¶] ¨S¦³½äŤ@§â¡A½ä¥X¤@Óµ²ªG ªGµM¤j³¡¥÷³£¬O¿é®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤U¤È 12:32:42
²Ä 4595 ½g¦^À³
|
¦Û¤v¥h¤ñ¹ï¬ã¨s,¥|¶gDUPILUMAB 1b ªvÀø³ø§i,«Å§i·§©À©ÊÁ{§É(MOA)¦¨¥\
1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10
www.nejm.org/doi/10.1056/NEJMoa1314768
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
2013¦~ dupilumab 1b ·§©À©ÊÁ{§É¦¨¥\³ø¾É
www.europeanpharmaceuticalreview.com/news/17492/sanofi-and-regeneron-report-positive-proof-of-concept-data-for-dupilumab/
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters. The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications. Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses). The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo). A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05). The most common adverse events (AEs) were nasopharyngitis (19.6% vs. 12.5% for placebo) and headache (11.8% vs. 6.3% for placebo).
¡§Despite existing therapies, a significant proportion of patients with moderate-to-severe atopic dermatitis continue to suffer from inflamed skin and intractable itch, which significantly impacts their quality of life,¡¨ said Dr. Eric Simpson, Associate Professor, Director of Clinical Studies, Oregon Health and Science University, Portland, Oregon, USA, and Principal Investigator of the study. ¡§The early phase results with this biologic therapy, which has a novel mechanism of action, are encouraging to those of us who treat these patients and warrant further clinical investigation.¡¨
¡§Through blockade of the IL-4alpha receptor, dupilumab modulates signaling of both the IL-4 and IL- 13 pathway, which have been implicated in the pathophysiology of allergic disease,¡¨ said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. ¡§We look forward to presenting additional data from a 12-week, Phase 2a trial in atopic dermatitis, as well as starting a larger Phase 2b trial with dupilumab in patients with atopic dermatitis, later this year.¡¨
Presented today in a late-breaking clinical trials session at the AAD meeting, the Phase 1b trials included 67 patients randomized to three different doses of dupilumab (75mg, n=8; 150mg, n=22; 300mg, n=21) and placebo (n=16). The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other endpoints included pharmacokinetic, biomarker, and efficacy parameters. Following the 4-week treatment period, patients in the studies were followed for an additional 4 weeks for a total of 8 weeks. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/9/30 ¤U¤È 12:24:09
²Ä 4594 ½g¦^À³
|
¤½¥q¥X¨ÓÁ¿³£·|Á¿¦nªº¥¿±` ¤§«e¸Ñª¼¥¢±Ñ¤]¥i¥HÁ¿¦¨¦nªº(¹ï¥¼¨Ó«áÄò¬ã¨s¦³¨M©w©ÊªºÀ°§U...) ©Ò¥H§Ú²{¦b³£¤£´±§¹¥þ¬Û«H ¥u§Æ±æ·à¤l®¶§@¤@ÂI¡A¦Ü¤Ö¼µ¤W¥h²{¼W»ù¡A¤£n¦AÄê¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/9/30 ¤U¤È 12:18:04
²Ä 4593 ½g¦^À³
|
½Ð±Ð¥ÕªÎ¤j¤j ¬°¦ó¼Æ¾Ú¦n«oªÑ»ù±Y½L¡A¹D²z«Ü²³æ¡A´N¬O¸ÑŪªº¤è¦¡¤£¤@¼Ë???
©Ò¥H¬O¡K¡K¡K¡K¡K¡K
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§We¡¦re delighted to report such positive data on ASLAN004. The data from the study wholly support our view that ASLAN004¡¦s novel mechanism could represent a new treatment option for patients suffering with moderate-to-severe AD, with the potential to deliver best-in-class efficacy and best-in-class safety. We look forward to building upon this strong data set as we initiate the Phase 2b study in the coming weeks and explore monthly dosing regimens that could provide additional convenience to patients.¡¨
¤½¥q°ª¼h©MªÑ»ù§@¤â¸ÑŪ ¤@¼Ë??? ¤£¤@¼Ë???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 11:59:32
²Ä 4592 ½g¦^À³
|
¤p·sÃĤ½¥q³Q¨ÖÁʤ~¯àÅã¥X»ùÈ!
¤p·sÃĤ½¥q³Q¨ÖÁʤ~¯àÅã¥X»ùÈ!
¤p·sÃĤ½¥q³Q¨ÖÁʤ~¯àÅã¥X»ùÈ!
-------------------------------------------------- IMMU-132¥«³õ»ùȳQ ¤é¥»²Ä¤@亖¦@ ADC ©Ò±a°_.
ªü´µ¯S±¶§Q±d 60»õ¬ü¤¸¤Uª`²Ä¤@¤T¦@ ¬D¾ÔImmunomedicsºÓTROP2¼Ð¹vADCÃÄ 2020.07.28Àô²y¥Í§ÞÂø»x/°OªÌ ´^±ê²[½sĶ
µoªí©ó 2020-07-28 §@ªÌ °OªÌ´^±ê²[ ¡X ¼ÈµL°jÅT ¡õ ªü´µ¯S±¶§Q±d 60»õ¬ü¤¸¤Uª`²Ä¤@¤T¦@ ¬D¾ÔImmunomedicsºÓTROP2¼Ð¹vADCÃÄ¡C ªü´µ¯S±¶§Q±d 60»õ¬ü¤¸¤Uª`²Ä¤@¤T¦@ ¬D¾ÔImmunomedicsºÓTROP2¼Ð¹vADCÃÄ¡C
¬ü°ê®É¶¡27¤é¡Aªü´µ¯S±¶§Q±d(AstraZeneca)«Å¥¬¦V²Ä¤@¤T¦@(Daiichi Sankyo)¤ä¥I10»õ¬ü¤¸¡A¦b¤é¥»¥H¥~¦a°Ï¦@¦P¶}µo§ÜÅéÃĪ«°¸ÁpÃĪ«(ADC)DS-1062¡C®Ú¾Ú¨óij¡AY¦¹ÃĪ«Àò±o§åã¡A²Ä¤@¤T¦@±NÃB¥~Àò±o10»õ¬ü¤¸¡A¥H¤Î40»õ¬ü¤¸¾P°â¬ÛÃö¨½µ{¸Oª÷¡C
DS-1062¬O¤@Ӽйv´þ¾i¼h²ÓMªí±§Üì2(trophoblast cellsurface antigen 2,TROP2)ªº§ÜÅéÃĪ«°¸ÁpÃĪ«¡A¥¦¬O¤@ºØ¸ó½¤³J¥Õ¡A·|¦bªÍÀù¡B¨Å¸¢Àù¡B¯Ø¸¢Àù©M¨ä¥L¾¹©xªº¸~½F¤¤¤j¶qªí²{¡A»P¹w«á¤£¨}¦³Ãö¡C
¦b¼Ð¹vTROP2»â°ì¬ã¨s¤¤¡A¶i®i³Ì§Ö§Y¬O¬ü°êImmunomedicsªºTrodelvy (sacituzumab govitecan)¨ä©ó¤µ¦~4¤ë¦bÂಾ©Ê¤T³±©Ê¨ÅÀù(mTNBC)ªvÀøªºÁ{§É¤T´Á¸ÕÅ礤¡A¦]®i²{¥XÅãµÛÀø®Ä¦Ó´£«e²×¤î¸ÕÅç¡A¦P¤ëFDA¤]¥[³t§åã³q¹LTrodelvy¤W¥«¡C
¥ý«e½÷·ç(Pfizer)¤]´¿¦³¤@´Ú§ÜTROP2 ªºADCÃĪ«¶i¤JÁ{§É¡A¦ý¦]¦´Á¼Æ¾Ú¤£¨Î«K¨ú®ø¸ÕÅç¡A¦]¦¹¥Ø«e¯à»PImmunomedics§Ü¿ÅªºÃĪ«¡A¬°²Ä¤@¤T¦@DS-1062²öÄÝ¡Aªü´µ¯S±¶§Q±d¹ï¦¹¤]±H¤©«p±æ¡C
¥Ø«e¸ÓÃĪ«¦b¤@´Á¸ÕÅ礤¡A34¦W±ß´Á«D¤p²ÓMªÍÀù¡]NSCLC¡^±wªÌ¦b8.0 mg / kg¾¯¶q²Õ¸ÕÅç¡A¦³38¢H¹ïDS-1062³¡¤À¦³®Ä(PR)¡A©Ò¦³±wªÌªº½w¸Ñ²v(RR)¬°25%¡F¦ý20%¨ü¸ÕªÌ¥X²{3¯Å©Î§óÄY«ªº¤£¨}¤ÏÀ³¡A¥]§t6¤H¥X²{¶¡½è©ÊªÍ¯e¯f(interstitial lung disease)¡A¤@¦W±wªÌ¦º¤`¡A¥Ø«e»{¬°»PªvÀø¦³Ãö¡C
¾¨ºÞ¥X²{¤£¨}¨Æ¥ó¡A¦ý²Ä¤@¤T¦@¦b¦´Á¼Æ¾Ú¤¤»{¬°¨ÌµM¦³¨¬°÷ªº¼ç¤OÄ~ÄòÂX®i¸Ó¬ãµopµe¡A±µ¤U¨Ó¦b§ó¤j¸s¤¤ªº¸ÕÅç¡A¤]±N¶i¦æ¾¯¶q»¼¼Wªº¬ã¨s¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 11:47:24
²Ä 4591 ½g¦^À³
|
IMMU-132 ADC---------(¯E¹©OBI999 ÁÞ¤À¤l ADC,15ºØÀù¯g)
2015¦~2¤ë ¨ú±oBTDªÑ»ù2.3¬ü¤¸/ªÑ((¦ô¥«È5»õ¬ü¤¸) 2020¦~3¤ë ªÑ»ù13¬ü¤¸/ªÑ((¥«È29»õ¬ü¤¸) 2020¦~4¤ë¨ú±o FDA Ãĵý ªÑ»ù30¬ü¤¸/ªÑ((¥«È68»õ¬ü¤¸)
2020¦~10¤ë 87¬ü¤¸/ªÑ³Q¨ÖÁÊ(¥«È200»õ¬ü¤¸)
FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast
www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer
On April 22, 2020, the Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.
Efficacy was demonstrated in IMMU-132-01 (NCT 01631552), a multicenter, single-arm, trial enrolling 108 patients with metastatic triple negative breast cancer (mTNBC) who received at least two prior treatments for metastatic disease. Patients received sacituzumab govitecan-hziy 10 mg/kg intravenously on days 1 and 8 every 21days. Tumor imaging was obtained every 8 weeks, and patients were treated until disease progression or intolerance to therapy. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ÕªÎ10142736 |
µoªí®É¶¡:2021/9/30 ¤W¤È 11:46:16
²Ä 4590 ½g¦^À³
|
¬°¦ó¼Æ¾Ú¦n«oªÑ»ù±Y½L¡A¹D²z«Ü²³æ¡A´N¬O¸ÑŪªº¤è¦¡¤£¤@¼Ë |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 11:33:38
²Ä 4589 ½g¦^À³
|
m.investing.com/equities/immunomedics-historical-data
Immu ¤½¥q¡AIMMU132/ADC¡A³Q200»õ¬ü¤¸¨ÖÁÊ¡A¬ù87¬ü¤¸/ªÑ¡C
¤@ADCªv¥|´Á3½u«áBNTC¡A·sÃĤ½¥q¡A¥H2´ÁÁ{§É¥Ó½ÐÃĵý¡AÀòFDAªºBTD(¬ð¯}©ÊÀøªk)¡A
·í2016/¦~02¤ë ÀòBTD®ÉªÑ»ù¶È2.32¬ü¤¸/ªÑ¡A ´¿¸g±NIMMU132¥þ²y¾P°âÅv20¦h»õ¬ü¤¸±ÂÅv¥X¥h¡AªÑ»ùº¦¨ì25¬ü¤¸¡A«á¨Ó¤jªÑªF¶}°£CEO¡A¤£¦P·N±ÂÅv¦X约¡A¤½¥q³Ì«á2050¦~ÀòÃĵý¡AªÑ»ùº¦¨ì40¬ü¤¸¡A³Ì«á³Q¨ÖÁÊ»ù87¬ü¤¸¥ª¥k¡C
·sÃĤp¤½¥q´N¬O³Q¨ÖÁʪѻù³Ì°ª
¦b¬ü°ê¥Í§ÞªÑ«Ü¥¿±`. IMMU-132 °µ§¹ 2´Á,2016/02/06®³¨ìBTD,ªÑ»ù2.32¬ü¤¸/ªÑ
www.adcreview.com/news/breakthrough-therapy-designation-for-sacituzumab-govitecan-in-triple-negative-breast-cancer/
Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer 2016/02/06
Mar 15 3.83 4.11 4.36 3.64 18.00M -6.13% Apr 15 3.60 3.80 4.39 3.56 17.73M -6.01% May 15 3.86 3.62 4.39 3.62 15.98M 7.22% Jun 15 4.06 4.08 5.05 3.85 30.66M 5.18% Jul 15 2.05 4.07 4.32 1.83 51.47M -49.51% Aug 15 2.16 2.05 2.24 1.69 23.05M 5.37% Sep 15 1.72 2.21 2.62 1.50 19.19M -20.37% Oct 15 2.99 1.70 3.09 1.59 21.52M 73.84% Nov 15 3.29 3.01 3.40 2.73 16.66M 10.03% Dec 15 3.07 3.30 3.33 2.66 15.69M -6.69% Jan 16 1.88 2.96 3.02 1.68 15.78M -38.76% Feb 16 2.26 1.87 2.49 1.61 24.49M 20.21% Mar 16 2.50 2.27 2.80 2.21 18.32M 10.62% Apr 16 3.55 2.47 3.86 2.43 21.14M 42.00% May 16 4.84 3.63 4.88 3.41 33.26M 36.34% Jun 16 2.32 4.87 5.44 1.95 95.69M -52.07% Jul 16 2.65 2.33 2.75 2.09 24.27M 14.22% Aug 16 2.77 2.66 3.15 2.60 19.89M 4.53% Sep 16 3.25 2.78 3.43 2.60 18.13M 17.33% Oct 16 2.30 3.21 3.39 2.06 61.00M -29.23% Nov 16 3.22 2.34 3.59 2.02 38.49M 40.00% Dec 16 3.67 3.22 4.10 3.01 32.31M 13.98% Jan 17 4.50 3.65 4.82 3.30 45.15M 22.62% Feb 17 5.00 4.50 5.89 4.08 107.54M 11.11% Mar 17 6.47 5.07 7.15 4.73 90.95M 29.40% Apr 17 5.73 6.53 6.53 5.00 39.59M -11.44% May 17 7.55 5.73 7.97 5.22 87.11M 31.76% Jun 17 8.83 7.53 9.04 7.26 54.69M 16.95% Jul 17 8.56 8.84 9.51 8.10 35.31M -3.06% Aug 17 12.64 8.56 12.66 7.17 72.27M 47.66% Sep 17 13.98 12.90 14.19 10.85 55.97M 10.60% Oct 17 10.72 14.05 14.48 10.22 51.27M -23.32% Nov 17 10.86 10.76 12.83 9.72 66.46M 1.31% Dec 17 16.16 10.69 17.05 8.68 87.42M 48.80% Jan 18 16.67 16.29 18.93 15.20 56.04M 3.16% Feb 18 16.91 16.61 17.42 14.06 40.79M 1.44% Mar 18 14.61 16.92 18.08 14.27 43.78M -13.60% Apr 18 18.21 14.51 18.80 13.82 37.37M 24.64% May 18 22.06 18.11 23.18 17.58 50.37M 21.14% Jun 18 23.67 22.27 26.48 22.10 81.53M 7.30% Jul 18 23.93 23.37 27.33 22.30 37.85M 1.10% Aug 18 26.76 23.77 26.76 20.73 32.45M 11.83% Sep 18 20.83 26.85 26.99 20.06 28.86M -22.16% Oct 18 22.53 20.99 24.15 19.24 43.12M 8.16% Nov 18 20.09 22.71 24.99 16.80 47.75M -10.83% Dec 18 14.27 20.60 21.23 12.86 54.81M -28.97% Jan 19 14.79 14.10 18.61 11.55 104.35M 3.64% Feb 19 15.76 14.71 16.61 13.55 48.56M 6.56% Mar 19 19.21 15.90 19.27 15.90 49.22M 21.89% Apr 19 16.02 19.31 19.51 15.15 49.24M -16.61% May 19 13.07 16.05 16.26 13.01 67.04M -18.41% Jun 19 13.87 12.85 14.05 11.59 64.24M 6.12% Jul 19 14.75 14.27 15.63 13.73 35.38M 6.34% Aug 19 12.80 14.73 16.05 12.47 39.92M -13.22% Sep 19 13.26 12.66 17.55 12.05 59.23M 3.59% Oct 19 16.00 13.21 16.64 12.43 46.10M 20.66% Nov 19 18.78 15.99 19.52 15.90 32.81M 17.38% Dec 19 21.16 18.88 22.22 17.22 67.45M 12.67% Jan 20 18.57 21.26 21.32 17.18 37.22M -12.24% Feb 20 16.00 18.75 20.46 14.58 28.52M -13.84% Mar 20 13.48 16.18 17.27 9.18 65.99M -15.75% Apr 20 30.38 10.86 31.56 8.80 191.25M 125.37% May 20 33.59 29.88 35.47 29.69 65.47M 10.57% Jun 20 35.44 33.20 37.25 29.55 95.03M 5.51% Jul 20 42.23 35.79 44.48 35.62 51.78M 19.16% Aug 20 44.56 42.86 44.91 39.40 29.84M 5.52% Sep 20 85.03 44.54 86.91 37.85 180.01M 90.82% Oct 20 87.86 85.03 87.93 84.91 15.32M 3.33% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2021/9/30 ¤W¤È 11:14:50
²Ä 4588 ½g¦^À³
|
³ø§i«ÂЬݤF¦n´X¹M¡A³£¬O¥¿±ªº¡A¯uªºµLªk¤F¸Ñ¬°¦ó¨S¤ÏÀ³¦bªÑ»ù¤W! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 10:29:38
²Ä 4587 ½g¦^À³
|
´Á¥¼PK ´Á¤¤
9/27 ASLAN004 600mg²Õ ,¨Ï¥ÎRITT+EEPP«á ,N=13¤H EASI 50= 100%(RITT-EEPP)(¤À¥À¦©°£3¦W--(¥¼§¹¦¨29¤ÑªvÀø/µû¦ô)¤Îç°£«D¶Ç²ÎAD 6¤H) EASI 75= 85%(RITT-EEPP) EASI 90= 46%(RITT-EEPP) IGA 0,1= 54%(RITT-EEPP)
°ò½u:IGA3/IGA4=56%/44% --------------------------- 3/1, ´Á¤¤600mg+400mg (N=3+6=9¤H)¼Æ¦r ,EEPP
EASI 50= 89%(EEPP)(¤£¥]§t¥¼§¹¦¨29¤ÑªvÀø/µû¦ô//¤£§t¤¤Â_±wªÌ) EASI 75=67%(EEPP) EASI 90=56%(EEPP) IGA 0,1=22%(EEPP)
°ò½u:IGA3/IGA4=67%/33%
ir.aslanpharma.com/static-files/327571f4-2df1-48b6-b922-f7cc2633882f
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/9/30 ¤W¤È 09:56:02
²Ä 4586 ½g¦^À³
|
¬O°Ú¡A·PÁ¤ѩR¤j¡A¬ã¨s³o¨Ç¼Æ¾Ú¹ê¦b¿N¸£ ¥Ø«e¤½¥q¦³003/004¨â´Ú·sÃĦb¶i¦æ ¤â¤W´¤¦³¨¬°÷²{ª÷§¹¦¨2bÁ{§É ´Nºâ©ú¦~¦³¥þ²yªºª÷¿Ä®ü¼S¤]¤£¼vÅT¶i«× ªÑ»ù¥H¤j¶^¤@¬q¡A´Nºâ¦A±Y¤@ªi¡A´N¦³¾÷·|¶R¨ì §ó«K©yªº»ù®æ
·ÀI³¡¤À´N¥u¯à¦Û¦æµû¦ô·Q¹³ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 09:46:49
²Ä 4585 ½g¦^À³
|
4.PÈ ,·í¦P¤ñ²v®É,·|ÀH¤H¼Æ¼W¥[¦Ó´î¤Ö.
¦pRITT
N=16:13 IGA0.1 ASLAN004 44%(N=16) VS ¹ï·Ó²Õ15%(N=13),P=0.107(¤£¹LÃö)
·íN=60:60---(2b ¤H¼Æ) IGA0.1 ASLAN004 44%(N=60) VS ¹ï·Ó²Õ15%(N=60),P=0.0005(¹LÃö)
¹êÅç¤H¼Æ¼vÅT¥ç«Ü¤j
©ñ¤j¨ì¤T´Á, N=200 : 200 ,p§ó¤p,
PÈ·U¤p,ªí¥Ü¨â²Õ¸ê®Æ©úÅã®t²§¾÷²v·U°ª.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/9/30 ¤W¤È 09:27:29
²Ä 4584 ½g¦^À³
|
Yang ¤j¡A
EASI 90 ¡Aªí¥Ü±q°ò½uªvÀø¶}©l´î¤Ö90%ªºªí±¬õ¸~¡K¡KAD¯g¡Aª¬¡A³o»Ý®É¶¡¡A¨Ì¾ÚLebrikizumab 8¶g¥i¤ÏÀ³¤j约630%,9-16¶g¡A¥t¥~¤W¤É15%¨ì45%¥ª¥k¡C
IGA0.1¦P¼Ë¡C
2.¨ü¤¤Â_²v19%.¼vÅT¡ADupilunab 3´Á220¤H¤¤断²v¶È7%.
3.ç°£9¤H¡A·íµM¦³¼vÅT¡A ITT22¤H 600mg¹êÅç组¡A§t6¦ì »´¤¤«×«D¶Ç²ÎAD±wªÌ¡AEASI90/IGA0/1¬Ò¥¼¹F¼Ð¡B ç°£«á6¦ì¹êÅç组«D¶Ç²ÎAD¡AIGA0/1±q27%¤É44%.
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial
jamanetwork.com/journals/jamadermatology/fullarticle/2761466
¦³x®É¶¡§Ç¦C,ªº¦U«ü¼ÐyÁÍ¶Õ ¹Ï,
0/4/8/12/16 ¶g. ¥idownload ÀÉ®×¥h¬Ý
Lebrikizumab 2b , Q2W*250MG ,
IGA 0,1 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.6%
EASI50 ²Ä8¶g¦b¬ù70%,²Ä16¶g81.0%
EASI75 ²Ä8¶g¦b¬ù44%,²Ä16¶g60.6%
EASI90 ²Ä8¶g¦b¬ù30%,²Ä16¶g44.0% |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 2001 ~ 2100 «h¦^ÂÐ >> |